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ABSTRACT 
The extracellular matrix (ECM) is a protein-rich network that provides information 
and structural support to the surrounding cells. Matrix metalloproteinases (MMPs) 
comprise a family of 23 human enzymes capable of degrading all components of the 
ECM. MMPs are essential for maintaining the indispensable balance between 
breakdown and production of ECM in physiological conditions, such as in 
reproductive processes and foetal development, but they can also create a neoplasm-
favouring milieu where cells can permeate degraded basement membranes, where 
novel partners for interactions are revealed and where tumour-promoting cytokines 
and growth factors are made available. 
We began this study by completing the human MMP family with MMP-21. As 
the roles of the novel MMPs are still rather enigmatic, we further wanted to define the 
expression profiles and inducing factors for the two most recent ones, MMP-21 and -
26, in physiological and pathological conditions of the skin and oesophagus in order 
to clarify their roles in epithelial biology. 
MMP-21 was not expressed under homeostatic conditions, during wound-
healing processes or in hyperproliferative or dysplastic conditions of the adult skin or 
oesophagus. During foetal development its expression was tightly regulated in a time 
and space related fashion and was confined to epithelial structures. Cancer cells at the 
invasive front of grades II and III squamous cell cancers (SCCs) of the skin and 
oesophagus expressed MMP-21. In cultured keratinocytes, transforming growth factor 
beta 1 induced MMP-21 expression. 
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MMP-26 was not expressed in normal resting epithelium, but migrating 
keratinocytes induced its expression during acute wound healing. Cellular atypia and 
inflammation upregulated MMP-26 expression in pre-malignant cutaneous lesions, in 
invasive cancer cells in skin and oesophageal SCCs of grades I and II and in 
oesophageal dysplasia. Tumorigenic progression abolishes MMP-26 expression, with 
grade III SCCs being devoid of it. 
Our research indicates that MMP-21 and MMP-26 play different roles in 
malignant transformation, and their expression profiles may help to identify patients 
needing more aggressive cancer treatment.  
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1. INTRODUCTION 
As early as in 1889 Stephen Paget proposed his well-known hypothesis for 
pathogenesis of cancer, the “seed and soil” hypothesis, in which he claimed abnormal 
interactions between tumour cells and the tissue environment are needed for 
attachment of the tumour to occur, explaining the non-random pattern of metastasis 
(Paget, 1889). Many studies of xenografted tumours, single nucleotide mutations of 
tumour suppressors and oncogenes have forced researchers to revisit the hypothesis, 
as the microenvironment seems to determine the success of malignant processes 
(Fidler, 2002). 
The research on matrix metalloproteinases (MMPs) began nearly half a 
century ago, when Gross and Lapière observed collagenolytic activity in a tadpole 
undergoing metamorphosis (Gross and Lapière, 1962). Since then, MMPs have been 
shown to be key players in the breakdown of barriers and supportive structures and in 
revealing novel cryptic sites of information needed for development and homeostasis 
of tissues as well as for establishment of many pathological conditions. Normal cells 
lack constitutive expression of MMPs, but their expression is upregulated in almost 
every type of human cancer (Egeblad and Werb, 2002). MMPs enzymatically degrade 
all components of the extracellular matrix (ECM). Balance between production and 
breakdown of ECM macromolecules is essential for all biological processes, and 
excessive proteolysis can cause or assist in the development of various pathological 
conditions, such as chronic inflammation, chronic wounds of the skin and intestine, 
arthritis, cardiovascular diseases and cancer. 
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The aim of this study was to identify novel members of the MMP family and 
to investigate their role in epithelial biology, determining whether they work for or 
against malignant processes. 
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2. REVIEW OF THE LITERATURE 
2.1. STRUCTURE OF THE SKIN AND OESOPHAGEAL MUCOSA 
The skin is composed of two layers, the outer layer being the epidermis, a stratified 
(containing multiple layers) squamous epithelium that overlays a layer of connective 
tissue, the dermis (Oikarinen and Tasanen-Määttä, 2003; McGrath et al., 2004) 
(Figure 1). The outer keratinized part of the epidermis functions as a barrier against 
drying, irradiation, mechanical, chemical or biological injury and foreign organisms. 
Barrier function is achieved by keratinocytes (KCs), which are organized in 10-20 
layers with four levels of differentiation: basal, spinous, granular and cornified. Basal 
stem cells in the epidermis give rise to transiently amplifying KCs, which after early 
differentiation in the spinous layer, start the apoptotic machinery and via late and 
terminal differentiation lose their nuclei in the granular layer, eventually dying and 
cornifying forming the stratum corneum of the epidermis (Nemes and Steinert, 1999) 
(Figure 1). The time for a KC to undergo differentiation and cornification after 
division in the basal layer is 52-75 days in normal skin, but can be many times faster 
in hyperproliferative disorders, such as psoriasis. KCs are the most abundant cells in 
the epidermis, constituting 95% of epidermal cells. The epidermis also contains 
pigment-producing melanocytes, antigen-recognizing Langerhans cells and touch-
sensitive neuroendocrine Merkel cells. The dermis consists of collagen, elastin, 
fibroblasts, blood vessels and adnexal structures (Oikarinen and Tasanen-Määttä, 
2003). 
The oesophageal mucosa is squamous and stratified in much the same way as 
the skin; the cells differ from skin KCs mainly by being non-keratinized, by having a 
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thicker proliferating basal layer and by expressing different keratin proteins (see Ross 
and Romrell, 1989; Rosai, 2004) (Figure 1). 
 
Figure 1. Schematic representation of skin and oesophageal epithelia (modified from 
Presland and Dale, 2000). 
 
2.1.1. Skin basement membrane zone  
The dermis and epidermis are compartmentalized, yet connected by basement 
membranes (BMs), which are self-assembling 50 to 100-nm-thick sheets of two 
networks linked by nidogen, the collagen (coll) IV and laminin (LN) networks. 
Covalently linked coll IV provide BMs with resistance to mechanical stress, whereas 
LN-polymers are essential for the adhesive properties of BMs (Yurchenko et al., 
2004). BMs can control the shape, proliferation, differentiation, migration, gene 
expression and apoptosis of epithelial cells. Basal cells connect to the BMs via 
hemidesmosomal complexes (Figure 2). LN-5, a major component of anchoring 
filaments, is connected to the cell surface via association with α6β4-integrin and 
extends to the basal lamina escorted by collagen XVII. LN-5 is unable to bind 
nidogen or coll IV, instead interconnecting with LN-6 or -7 to incorporate itself into 
nidogen and eventually coll IV (Timpl, 1996; Ghohestani et al., 2001). 
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 Figure 2. Schematic representation of the cutaneous basement membrane zone (modified 
from Ghohestani et al., 2001). 
 
2.1.2. Extracellular matrix 
All cells of the body are embedded in a tissue-specific extracellular matrix (ECM). 
Fibroblasts secrete components of dermal ECM, including collagens, elastin, laminins 
and other fibrous proteins embedded in networks of large glycoproteins. The ECM is 
a well-organized web of solid-state support for cells, it is a reservoir of bound 
cytokines and growth factors and it carries cryptic information that can be cleaved by 
proteinases to give rise to fragmented molecules with novel bioactivities. Adhesion of 
cells to each other is primarily a function of E-cadherin (=epithelial calcium-
dependent adhesion molecule) and the associated catenin complex (α−, β− and 
γ−catenins and catenin-like p120ctn) (Beavon, 2000). As ECM is proteolysed, 
interactions between cells are lost and new interactions between cells and the 
surrounding matrix arise, promoting diverse cellular functions including migration, 
proliferation and differentiation. ECM remodelling is essential in many physiological 
conditions, including reproduction, wound healing, angiogenesis and foetal 
development, but it is also responsible for tissue destruction in such pathological 
conditions as chronic wounds, atherosclerosis, cancer invasion and metastasis (Timpl, 
1996; Kalluri, 2003; Radisky and Bissell, 2004).  
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2.2. CUTANEOUS WOUND HEALING 
Wounding is essentially a loss of integrity within a tissue, affecting the skin, mucosa 
or organs. The complex processes of healing aim at repair of the damage that occurs 
in overlapping phases of inflammation, proliferation, migration, matrix synthesis and 
contraction; repair usually takes 1-2 weeks (Martin, 1997) (Figure 3). As wounding 
disrupts the integrity of blood vessels, bleeding occurs, activating the blood 
coagulation system and rapidly leading to clot formation. The primary function of the 
fibrin clot is termination of bleeding (Hatz et al., 1994; Martin, 1997). The clot is 
transformed into granulation tissue as neutrophils, monocytes, plasma cells, mast 
cells, fibroblasts and endothelial cells invade the clot and fill it with blood vessels and 
a novel provisional matrix. Neutrophils and other granulocytes defend the wounded 
site against micro-organisms (Hatz et al., 1994; Martin, 1997). KCs surrounding the 
wounded area begin to migrate along the novel matrix between the clot remnants and 
granulation tissue within 3-6 h of injury (epithelialization). As KCs migrate, basal 
cells distal to them start proliferating. Once the wounded area is covered by a 
monolayer of KCs, the suprabasal KCs undergo a standard differentiation program, 
leading to reconstitution of the squamous stratified epithelium at the site of injury 
(Hatz et al, 1994; Martin, 1997). Wound contraction occurs next, with fibroblasts 
differentiating into myofibroblasts, which contract and bring the wound margins 
together. The reparative phase is the last stage in wound healing; fibroblasts in the 
dermis produce new connective tissue, i.e. collagen fibrils. As collagen matures, cell 
density and vascularization of the wound decrease and scar formation results (Figure 
3).  
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 Figure 3. Schematic representation of wound healing. 1) Intact skin with collagen arranged in 
networks. 2) Clot formation and rapid filling with neutrophils and macrophages. 3) 
Fibroblasts and endothelial cells invade the clot and deposit the granulation tissue. 4) 
Simultaneously, keratinocytes begin to migrate along the wound matrix deposited by 
fibroblasts, and distal keratinocytes start proliferation. 5) Contact inhibition seizes the 
migration of keratinocytes and normal differentiation begins to form a neo-epidermis. At this 
time fibroblasts differentiate into myofibroblasts, which subsequently contract to bring the 
wound margins together. 6) Fibroblasts have remained in the granulation tissue and secreted 
novel extracellular matrix, whose collagens are in tight bundles instead of the network 
architecture in intact skin (modified from Werner and Grose, 2003). 
 
Wound healing employs many processes also essential in tumorigenesis endothelial 
cell invasion in granulation tissue formation and angiogenesis in tumorigenesis, KC 
migration and proliferation in epithelialization and invasion and metastasis in tumour 
progression, and the fibrin-induced infiltration of endothelial cells, macrophages and 
fibroblasts during both wound healing and tumour progression (Dvorak, 1986). 
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2.3. CARCINOMAS 
2.3.1. Tumorigenesis and invasion 
Tumorigenesis is a complex multistep process involving genetic changes, selection of 
malignant cell populations and modifications in the environment that favour 
malignant progression (Hanahan and Weinberg, 2000) (Figure 4).  
 
Figure 4. Malignant properties acquired by most cancers during their development 
(modified from Hanahan and Weinberg, 2000). 
 
One of the first steps towards malignancy is the epithelial to mesenchymal transition 
(EMT), resulting in free movement of the formerly tightly bound epithelial cells. The 
ECM works as a barrier to free cell movement, and in order to migrate, cells need to 
activate their cytoskeletal motors for movement, modulate their cell-surface adhesion 
molecules for traction, cleave ECM to break the barrier and respond to 
chemoattractants for guidance of migration (Vu and Werb, 2000). A primary tumour 
can reach a maximum size of 1-2 mm without a blood supply. Angiogenesis results 
from hypoxia-induced expression of basic fibroblast growth factor (bFGF) and 
vascular endothelial growth factor (VEGF), growth factors that promote endothelial 
cell recruitment (Wyke, 2000). Tumour neovasculature leaks more than normal 
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vasculature, thus being more efficient in delivery of oxygen to the tumour, but as its 
endothelial cells proliferate rapidly, they also respond better to anti-angiogenic 
therapies than the normal vasculature (Sternlicht et al., 1999). Metastatic processes 
are dependent on stromal cells, endothelial cells, the environment of the tumour cells 
and the tumour cells themselves. The processes are also dependent on interactions 
between these components and the balance between steps acting for and against 
metastasis (Hanahan and Weinberg, 2000). Stromal cells, infiltrating immune cells 
and tumour cells are all capable of synthesizing the MMPs necessary for invasion 
through the BMs, to lymph and blood vessels (Egeblad and Werb, 2002). Tumour 
infiltrates extravasate in a tissue-specific way according to the “seed and soil” 
hypothesis of cancer development, initially presented in 1889 (see Fidler, 2002). 
2.3.2. Pre-malignant and malignant lesions of the skin  
The most common skin cancer worldwide is basal cell carcinoma (BCC). In Finland, 
5000-5500 new cases of BCC are detected annually, accounting for approximately 
22% of all new cancer cases (Finnish Cancer Registry, www.cancerregistry.fi). BCCs 
grow slowly, cause local skin destruction and rarely metastasize. They are believed to 
arise from transformed basal stem cells of the epidermis or hair follicles, and they 
occur in both a sporadic and an inherited fashion (Bäckvall et al., 2005). 
Histologically, BCCs can be divided into nodular, superficial and aggressive 
sclerosing (morpheaform) subtypes (Weedon, 2002). The genetic hallmark for BCCs 
is a loss-of-function mutation for ptch, a member of the sonic hedgehog-signalling 
pathway (Boukamp, 2005). BCCs are primarily treated by surgical removal of the 
tumour or cryotherapy with liquid nitrogen. 
Squamous cell carcinoma (SCC) arises from an unidentified progenitor, 
possibly a stem cell, and is often the result of cumulative sun exposure. The 900 new 
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cases of SCCs a year account for 3% of all new cancer cases in Finland (Finnish 
Cancer Registry). SCCs grow quickly and the development is a step-wise process 
consisting of squamous cell dysplasia (actinic keratosis), severe dysplasia (carcinoma 
in situ), invasive SCC and metastasizing SCC (Bäckvall et al., 2005). Hot spot 
mutations in the p53 gene are common among SCC patients, occurring early during 
tumorigenesis (Greenblatt et al., 1994). Transgenic animals with mutations in their 
p53 alleles have induced susceptibility to develop SCC in response to UV-irradiation, 
without changes in the latent period before tumour development (Li et al., 1995). A 
further mutation that occurs with progression of actinic keratosis to SCC is loss of 
heterogeneity in tumour suppressor p16INK4a (Mortier et al., 2002). As SCC is more 
frequent in immunosuppressed patients, “dormant” SCC precursors have been 
suggested to exist in normal skin and to be under control of the immune system 
(Boukamp, 2005). SCCs demand surgical removal of the tumours, with at least 5-mm 
margins of healthy skin. 
Bowen’s disease is a carcinoma in situ type of lesion that is characterized by 
cellular atypia and frequent mitoses. The BM remains intact and the tumour can be 
treated by surgical removal or by crytreatment with liquid nitrogen (Kane et al., 
2004). 
Keratoacanthoma (KA) is a rapidly growing benign squamous neoplasm, often 
present on sun-exposed skin. It develops rapidly (4-8 weeks) and can regress 
spontaneously after 3-6 months (Schwartz, 2004). KAs have less complex molecular 
and cytogenetic changes than SCCs, suggesting that they are genetically incomplete 
SCCs (Boukamp, 2005). As some KAs become aggressive carcinomas and the 
malignant behaviour is unpredicatble, all KAs are treated by surgical removal of the 
tumour (Kane et al., 2004; Schwartz, 2004). 
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2.3.3. Pre-malignant and malignant lesions of the oesophagus 
Intraepithelial neoplasia of the oesophagus is frequently a precursory lesion of 
oesophageal squamous cell carcinoma (ESCC) in high-risk areas and is typically 
found adjacent to an invasive ESCC. It has cytological and architectural abnormalities 
and is characterized by a disorganized epithelium and cells with irregular and 
hyperchromatic nuclei and high mitotic activity. Dysplasia can be graded as low- or 
high-grade, depending on the severity of the atypical changes. In carcinoma in situ, 
the entire thickness of the epithelium presents with dysplasia, without evidence of 
maturing cells at the surface (Mandard et al., 1984). 
ESCC is a highly malignant tumour located in the thoracic oesophagus. 
Approximately 200 new cases of ESCC are diagnosed annually in Finland, accounting 
for less than 1% of all new cancer cases (Finnish Cancer Registry). Behaviours 
resulting in chronic irritation and inflammation of the oesophagus, such as smoking 
and heavy drinking, are risk factors for ESCC (Launoy et al., 1997). At the time of 
initial diagnosis, the cancer often exhibits extensive local invasion and metastases to 
regional lymph nodes (Enzinger and Mayer, 2003). Surgery frequently provides only 
palliation of the symptoms. And the registered 5-year survival rates are around 10% 
(Hamilton and Aaltonen, 2000). 
2.4. MATRIX METALLOPROTEINASES 
Completion of the Human Genome Project has resulted in the discovery of 20 000-25 
000 human genes, more than 2% of these being proteases or protease inhibitors, 
emphasizing the importance of regulated degradation of macromolecules in processes 
as diverse as reproduction, development, host defence, inflammatory diseases, 
neurological disorders and cancer (Puente et al., 2005). Matrix metalloproteinases 
(MMPs) are a family of 23 human endopeptidases capable of degrading all 
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components of the ECM, and the number of non-ECM substrates for MMPs is 
expanding continually (Overall and Lopéz-Otín, 2002). MMPs are usually absent 
from normal healthy tissue, but are detected in all repair and remodelling processes 
and in most cultured cell types (Parks et al., 2004). MMPs and their natural inhibitors, 
tissue inhibitors of metalloproteinases (TIMPs), participate in all processes of tumour 
development depicted in Figure 4, including loss of cell adhesion, escape from 
apoptosis, loss of cell growth control, alterations in responses to anti-growth signals 
and cleavage of barriers to invasion and metastasis. 
Based on their structural features, MMPs are divided into five subgroups: 
collagenases, gelatinases, stromelysins, matrilysins and membrane-type MMPs (MT-
MMPs) (Figure 5). Novel members of the family, such as MMP-19 (Pendás et al., 
1997), - 23 (Velasco et al., 1999), and -28 (Lohi et al., 2001), often contain additional 
structural elements, making them unsuitable for any of the pre-existing subclasses. 
The basic structural units that an enzyme must have to be an MMP are the pro-domain 
with a Cys-switch for preservation of latency and the catalytic domain containing 
three histidines to bind the Zn2+ ion needed for activity. In addition, all but the 
matrilysins have a haemopexin domain. The pro-peptide release and thereby 
activation of MMPs can be achieved with proteinases (also MMPs acting on each 
other or autolytically) or with chaotropic agents (Vu and Werb, 2000). 
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Figure 5. Structural subgroups of matrix metalloproteinases (modified from Vu and Werb, 
2000). 
 
MMP-1, -8 and -13 are collagenases with amino acids Tyr214, Asp235 and Gly237 
(numbering in MMP-13) in their catalytic domain, enabling binding of the triple-
helical structure of native fibrillar collagens in a way sensitive to proteolysis. Non-
collagenous substrates for collagenases include aggregan and MMP-inhibitor α2-
macroglobulin (Vu and Werb, 2000; Kerkelä and Saarialho-Kere, 2003) (Table 1). 
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MMP-2 and -9 are gelatinases with three fibronectin-like inserts in their 
catalytic domain to enable degradation of denatured collagens. Gelatinases cleave also 
the abundant BM protein collagen IV and release TNF-α and other growth factors 
from their precursors (Vu and Werb, 2000: Kerkelä and Saarialho-Kere, 2003) (Table 
1).  
MMP-3, -10 and -11 are stromelysins with the characteristic amino acid insert 
XPPVPTXXV in the C-terminal end of their catalytic domain to enable degradation 
of non-collagen ECM substrates such as E-cadherin, LN-1 and type IV collagen (for 
MMP-3) (Vu and Werb, 2000; Kerkelä and Saarialho-Kere, 2003) (Table 1).  
MMP-7 and -26 are matrilysins, the smallest MMPs as they lack the 
haemopexin domain, making their substrate specificity exceptionally wide, including 
Fas-ligand, pro-α-defensins and macromolecules harbouring growth factors (Vu and 
Werb, 2000; Kerkelä and Saarialho-Kere, 2003) (Table 1).  
MMP-14, -15, -16, -17, -24 and -25 are MT-MMPs. Their catalytic activities 
occur on cell surfaces, and they are bound to cell surface either by a transmembrane 
domain or by a specific glycosyl-phosphatidyl-inositol (GPI) anchor. MMP-14 has 
been shown to specifically activate MMP-2 (Vu and Werb, 2000; Kerkelä and 
Saarialho-Kere, 2003) (Table 1). 
Other family members form the group of novel MMPs characterized by a furin 
cleavage site (MMP-21 and -28), novel inserts of, for example Ig-like motifs or 
unclassical Cys-switches (MMP-23A/B) in their pro-domain (Overall and Lopéz-
Otín, 2002). Physiological substrates for many of the novel MMPs remain to be 
elucidated. Known substrates and chromosomal locations for all MMPs are listed in 
Table 1. 
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Table 1. Chromosomal locations and substrates for human matrix metalloproteinases 
(modified from Kerkelä and Saarialho-Kere, 2003; with additional data from Lohi et al., 
2001; Marchenko et al., 2003; Sadowski et al., 2005). 
 
MMP 
Chromosomal 
Location Substrates 
MMP-1 11q22.3 
Col I*, II*, III, VII, VIII, X, aggregan, MBP, serpins, α2M, perlecan, pro-TNF-α, 
IGFBP, α1P1, entactin/nidogen, vitronectin, tenascin, fibrinogen 
MMP-2 16q13-q21 
Col I, IV, V, VII, X, gelatin, FN, tenascin, fibrillin, osteonectin, entactin, aggregan, 
vitronectin, plasminogen, MBP, decorin, α2M, LN-5, IGFBP, pro-TNF-a, pro-TGF-
β*, α1PI, chemokine ligands CCL* and CXCL* 
MMP-3 11q22.3 
Col III, IV*, V, VII, IX, X, elastin, FN, fibrillin, gelatin, aggregan, LN-1*, nidogen, 
osteonectin, decorin, α1PI, pro-TNF-α, MBP, E-cadherin*, β-catenin, IGFBP, 
fibrinogen, vitronectin, tenascin, plasminogen 
MMP-7 11q21-q22  
Col IV, elastin*, FN, LN-1, entactin, aggregan, vitronectin, versican, nidogen, 
tenascin, versican, α1PI, osteopontin, MBP, decorin, osteonectin, E-cadherin*, 
plasminogen, β4-integrin, pro α-defensin*, Fas ligand*, pro-TNF αsyndecan-1* 
MMP-8 11q22.3 Col I, II, III, aggregan, serpins,α2M, fibrinogen, mouse chemokine ligand CXCL* 
MMP-9 20q11.2-q13.1 
Col I, IV, V, VII, XI, XIV, XVII, elastin, FN, fibrillin, gelatin, osteonectin, 
aggregan, vitronectin, α1PI*, pro-TNF-α, MBP, IGFBP, α2M, plasminogen, TGF-β, 
decorin, pro-VEGF*, fibrin* 
MMP-10 11q22.3 LN5γ2, Col III, IV, V, IX, X, XIV, elastin, FN, gelatin, aggregan, LN-1, nidogen 
MMP-11 22q11.23 α1PI, IGFBP 
MMP-12 11q22.3 
Elastin, Col IV, FN, LN-1, gelatin, vitronectin, entactin, proteoglycan, heparan and 
chondroitin sulphates, pro-TNF-α, plasminogen, fibrillin, fibrinogen, α1PI 
MMP-13 11q22.3 
Col I*, II*, III, IV, IX, X, XIV, aggregan, fibrillin, FN, gelatin, LN-1, large tenascin 
C, osteonectin, serpins, PAI, fibrinogen 
MMP-14 14q11-q12 
Col I*, II*, III*, gelatin, FN, LN-1, LN5γ2*, vitronectin, aggregan, tenascin, nidogen, 
perlecan, fibrinogen/fibrin*, fibrillin, α1PI, α2M, CD44, pro-MMP-2*, syndecan-1* 
MMP-15 16q13-q21 FN, LN-1, gelatin, aggregan, tenascin, nidogen, perlecan, vitronectin , fibrin* 
MMP-16 8q21  
Col III, FN, gelatin, LN1, aggregan, casein, vitronectin, α2M, α1PI, fibrin*, 
syndecan-1* 
MMP-17 12q24.3 Gelatin, pro-TNF-α , fibrillin, FN 
MMP-19 12q14  Col IV, gelatin, LN1, nidogen, tenascin, FN, aggregan, COMP, fibrinogen, LN5γ2 
MMP-20 11q22.3 Amelogenin*, aggregan, COMP 
MMP-21 10q26.2  α1-antitrypsin 
MMP-23A/B 1p36.3 Aggregan, COMP, gelatin 
MMP-24 20q11.2  Heparan and chondroitin sulphates, gelatin, FN 
MMP-25 16p13.3 Col IV, gelatin, FN, fibrin, vitronectin,α1PI, LN1 
MMP-26 11p15 Col IV, gelatin, FN, fibrin, α1PI, β-casein, TACE-substrate, pro-MMP-9 
MMP-27 11q24 ND 
MMP-28 17q11-q21.1 casein 
FN, fibronectin; LN-1, laminin-1; LN5γ2, gamma-2-chain of laminin-5; Col, collagen; IGFBP, insulin-like growth factor 
binding protein; MBP, myelin binding protein; COMP, cartilage oligomeric matrix protein; PAI, plasmin activator 
inhibitor; TACE, TNF-α converting enzyme; α2M, α2-macroglobulin; α1PI, α1-proteinase inhibitor; ND, not 
determined; *, substrates verified by mutagenesis or overexpression studies (Parks et al., 2004). 
Chromosomal locations from the National Centre for Biotechnology Information (NCBI) database 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene). 
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 2.4.1. MMP-26 
MMP-26, also known as matrilysin-2 or endometase, is a recent addition to the MMP 
family. The gene for MMP-26 is located in the short arm of the chromosome 11, a site 
distinct from the cluster of classical MMPs in 11q21-23, and codes a 261-amino-acid-
long enzyme with the signal sequence for secretion, the pro-domain and the catalytic 
domain. MMP-26 can undergo autocatalytic activation, an exceptional feature among 
MMPs (de Coignac et al., 2000; Park et al., 2000 and 2002; Uría and Lopéz-Otín, 
2000). 
 In vitro substrates for MMP-26 include native coll IV, denaturated collagens I-
IV, fibronectin, fibrinogen, vitronectin, α1-antitrypsin, α2-macroglobulin and insulin-
like growth factor binding protein 1. Furthermore, MMP-26 cleaves pro-MMP-9 in a 
specific site to create gelatinase species with unusually stable activity. Proteins 
resistant to MMP-26 activity include LN5, tenascin C and native collagens I-III. 
MMP-26 can be inhibited by TIMP-2 and –4 (Marchenko et al, 2001 and 2002). 
 MMP-26 is expressed in the prostate and endometrium under physiological 
conditions and in the corresponding cancers. Other tissues expressing MMP-26 
include the placenta, lungs, kidneys and uterus (Zhang et al, 2002; Isaka et al, 2003; 
Pilka et al, 2003; Tunuguntla et al, 2003; Zhao et al, 2003). MMP-26 seems to 
participate in the reproductive processes and in malignant processes. 
2.4.2. Inhibition of MMPs 
MMPs are powerful degrading enzymes of the ECM, and accordingly, their activities 
are tightly regulated at all production levels. Transcription and translation are 
controlled by cytokines, growth factors, matrix substances and other stimuli. Between 
 26
secretion and action, MMPs are kept inactive by disulphide bridging between Cys-
residues in the pro-domain and in the catalytic centre. Once activated, MMPs can be 
inhibited by one of the four existing TIMPs, by the reversion-inducing cysteine-rich 
protein with Kazal motifs (RECK) (Noda et al., 2003), by attraction to scavenger 
receptors via the plasma protein α2-macroglobulin (Hojilla et al., 2003), by 
chemically modified tetracyclines and by bisphosphonates (see Vihinen et al., 2005) 
and by specially designed molecules, such as the patented CTT peptide (Björklund et 
al., 2004; Medina et al., 2005). 
2.4.3. Expression of MMPs during tissue homeostasis  
Most adult tissues are kept in a relatively dormant balance between cell death and 
renewal, with very low expression levels of MMPs. Wounding disrupts the balance 
and activates the reparative machinery to replace lost tissue and repair the wounded 
area. The steps in the process of wound healing (see Figure 3) necessitate the action of 
MMPs. Invasion of endothelial cells into the fibrin clot is dependent on MMP-14 
(Hotary et al., 2002). Migrating KCs at the leading edge of the wound facilitate the 
migration by secreting MMP-1, -9 and -10 (Parks, 1998), whereas the proliferating 
basal KCs distal to the migrating tip express MMP-3, -19 and -28 (Parks, 1998; 
Saarialho-Kere et al., 2002; Hieta et al., 2003;).  
The regulated proliferation, tissue contractions, foldings and migrations 
essential for proper wound healing are also essential for embryonic morphogenesis 
(Martin and Parkhurst, 2004). In addition, the reproductive processes necessitate 
extensive reorganization of the extracellular surroundings, whether during gestation, 
implantation of the embryo, parturition or cycling of the endometrium (see Vu and 
Werb, 2000). Dissection of developing murine tissues has revealed a rather ubiquitous 
expression of MMPs 14-16 and TIMPs, whereas abundant expression of MMP-2 is 
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restricted to the heart, lungs, kidneys and muscle; of MMP-19 to the lungs, liver and 
testes; of MMP-11 to the lungs, uterus and testes; and of MMP-23 to the reproductive 
tissues. MMP-26 lacks the murine counterpart, but its closest structural relative, 
MMP-7, has the highest expression levels in the uterus (Nuttall et al., 2004). 
2.4.4. Expression profiles of MMPs in epithelial cancers of the skin and 
oesophagus 
The ECM carries critical controlling information for cell adhesion, differentiation, 
proliferation and apoptosis, and accordingly, disruptions of the ECM increase 
tumorigenic potential  (Hojilla et al., 2003). MMPs are located at the cell-ECM 
interface and have been proven to cause alterations in cell attachment to the ECM in 
cancer. They can also cleave molecules situated between the ECM and the 
intracellular cytoskeleton, thereby breaking cells’ connections with neighbour 
surveillance (Mott and Werb, 2004). The significance of MMPs in tumour biology 
was highlighted by the metastatic potential of cancer cells being correlated with their 
degradative potential against BM collagen IV, today known to be cleaved by 
gelatinases MMP-2 and -9 (Liotta et al., 1980; Overall and Lopéz-Otín, 2002). Many 
of the members of the human MMP family were isolated from tumours or tumour cell 
lines, were upregulated by cytokines abundantly expressed during malignant 
transformation (Mueller and Fusenig, 2004) or were found to have binding sites for 
transcription factors that are often activated in malignant processes (Marchenko et al., 
2002). Recent research has evidenced the role of MMPs in all stages of tumour 
progression, including initiation, growth, cell migration and angiogenesis, with 
individual MMPs having roles for or against tumour growth and invasion (Egeblad 
and Werb, 2002; Overall and Lopéz-Otín, 2002). The production of certain MMPs is 
an early event in tumour development. Immune cells produce angiogenic factors when 
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accumulating in the vicinity of neoplastic cells – even before the MMP-9-dependent 
angiogenic switch (Bergers et al, 2000; Kalluri, 2003).  
In BCCs, the upregulation of MMP-1 in the stromal compartment is an early 
event, whereas epithelial expression of MMP-3, -7 and -10 occurs only in the most 
aggressive subtype, thus being associated with further acquisition of malignant 
properties (see Kerkelä and Saarialho-Kere, 2003). 
In SCCs, the imbalance between MMPs and their inhibitors is well 
documented; high MMP levels correlate with more aggressive tumours (Johansson 
and Kähäri, 2000). Upregulation of MMP-1 is an early event, occurring at the stage of 
actinic keratosis, whereas epithelial expression of MMP-2, -3 and -10 requires further 
dedifferentiation, as they are absent from premalignant conditions preceeding SCC 
(Tsukifuji et al., 1999; Kerkelä et al., 2001).  
Expression of MMP-7, a structural relative of MMP-26, correlates with 
recurrence and poor prognosis of ESCC patients, and co-expression of it and MMP-9 
at the invasive front shortens survival significantly (Etoh et al., 2000; Tanioka et al., 
2003), although MMP-9 expression alone does not correlate with poor prognosis 
(Yamashita et al., 2004).  
An essential acquired malignant feature of SCCs is their tendency to 
metastasize and invade through BMs, and accordingly, SCCs frequently present with 
decreases in coll IV and increases in MMP-2 and -9 levels, as compared with the less 
malignant KC-derived cancers (Dumas et al., 1999; Samantaray et al., 2004). 
Cancer cells stimulate host cells to express and secrete MMPs rather than 
producing MMPs themselves. Instead of being the ultimate cause of malignant 
behaviour, MMP overproduction is now seen as one of the responses of stromal cells 
to stimuli from tumour cells (Pavlaki and Zucker, 2003).  
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2.4.5. Transgenic studies for MMPs and TIMPs 
Studies with transgenic animals have sometimes yielded contradictory roles for 
MMPs in tumour development. Several MMP knock-outs have shown reduced 
tumorigenesis of various cancer types such as intestinal tumours for MMP-7-null 
animals (Wilson et al., 1997), chemically induced fibrosarcomas for MMP-19-null 
animals (Pendás et al., 2004), chemically induced mutagenesis cancers for MMP-11-
null animals (Masson et al., 1998) and melanomas for MMP-2- and MMP-9-null 
animals (Itoh et al., 1998 and 1999). Conversely, other MMP knock-out mice have 
manifested an increase in tumorigenesis, e.g. MMP-8-null male and MMP-3-null 
animals for chemically induced skin cancers (Balbín et al., 2003; McCawley et al., 
2004). Our group has demonstrated that MMP-19 disappears upon dedifferentiation of 
human SCCs (Impola et al., 2003). Yet the MMP-19-null mouse shows a decrease in 
susceptibility to chemically induced tumours, contradicting the role of this MMP in 
protection from cancer (Pendás et al., 2004). TIMP-1 by virtue of its inhibitory effect 
on MMPs could easily be considered a protector against tumorigenesis. However, its 
overexpression in a skin cancer model promotes carcinogenesis in K14-HPV16 mice 
by potentiating keratinocyte proliferation (Rhee et al., 2004). Selection of appropriate 
methods for inactivating or potentiating a given gene to fight cancer in becoming 
increasingly complicated with studies uncovering new phenotypes of transgenic 
animals. Major published MMP- and TIMP-transgenic genotypes and phenotypes are 
listed in Table 2. 
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Table 2. MMP- and TIMP-transgenic mice and their phenotypes with references to original 
articles (modified from Vu and Werb, 2000). 
 
Genotype Phenotype Reference 
MMP-1 
overexpression Increased incidence of chemically induced skin tumours D’Armiento et al., 1995 
MMP-2 null 
Reduced tumour-induced angiogenesis, delayed mammary gland development,
decreased pancreatic tumour growth in RIP-Tag mice 
 
Itoh et al., 1998; Bergers et 
al., 2000; Sternlicht and 
Werb, 2001  
MMP-3 null 
Impaired wound contraction, enhanced initial growth, aggressive behaviour in
chemically induced SCC 
 Bullard et al., 1999; 
McCawley et al., 2004 
MMP-3 
overexpression 
Increased incidence of mammary tumour development or reduced incidence of Witty et al., 1995; Sternlicht 
et al., 1999 chemically induced mammary tumours 
MMP-7 null 
Reduced innate intestinal immunity, impaired mucosal wound re-
epithelialization, reduced intestinal tumorigenesis 
Wilson et al., 1997; 
Dunsmore et al., 1998; 
Wilson et al., 1999 
MMP-7 
overexpression Enhanced Neu-induced mammary tumorigenesis Rudolph-Owen et al., 1998 
MMP-8 null Increased susceptibility to chemically induced skin tumours in male mice Balbín et al., 2003 
MMP-9 null  
Delayed and reduced skin tumorigenesis, but more aggressive tumours,
delayed bone development, reduced pancreatic tumorigenesis in RIP-Tag mice 
 Vu et al., 1998; Bergers et al., 
2000; Coussens et al., 2000  
MMP-10 
overexpression Disorganized migrating tip in wounds, aberrant LN-5 deposition Krampert et al., 2004 
MMP-11 null 
Reduced susceptibility to chemically induced cancer of the mammary gland 
and ovary  Masson et al., 1998 
MMP-12 null Reduced susceptibility to smoking-induced emphysema Hautamäki et al., 1997 
MMP-13 null Delayed bone development Inada et al., 2004 
MMP-9 and MMP-13 
null Abnormal bone formation Stickens et al., 2004 
MMP-14 null Impaired skeletal development and angiogenesis, lethal by 3 weeks of age Holmbeck et al., 1999 
MMP-14 
overexpression Increased mammary hyperplasia, dysplasia, adenocarcinoma Ha et al., 2001 
MMP-19 null 
Diet-induced obesity and reduced susceptibility to chemically induced skin 
cancer Pendás et al., 2004 
MMP-20 null Abnormal tooth development and morphology Caterina et al., 2002 
TIMP-1 null Increased lung injury after bleomycin exposure, abnormal menstrual cycling 
Nothnick, 2000; Kim et al., 
2005 
TIMP-1 
overexpression 
Increased incidence of tumours in K14-HPV16 mice, decreased chemically
induced mammary tumorigenesis, decreased liver carcinogenesis 
 
Martin et al., 1996; Rhee et 
al., 2004; Yamazaki et al., 
2004 
TIMP-2 null Deficient MMP-2 activation Wang et al., 2000 
TIMP-3 null 
Impaired branching morphogenesis of the lungs, accelerated apoptosis in
mammary glands, impaired lung function 
 Fata et al., 2001; Leco et al., 
2001; Gill et al., 2003 
RECK null 
Embryonic lethality, reduced integrity of vasculature, neural tube and 
mesenchymal tissues Noda et al., 2003 
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3. AIMS OF THE STUDY 
The main goals of this research were to identify any remaining members of the MMP 
family and to characterize the roles of the two newest MMPs, MMP-21 and MMP-26, 
in epithelial biology, especially in malignant processes. The expression profiles of 
novel MMPs must be carefully examined in tissue turnover before MMP regulation or 
inhibition can be considered for therapeutic purposes. Specific aims of the study were 
as follows: 
 
I) To complete the human MMP enzyme family with MMP-21 and to examine the 
role of MMP-21 in remodelling processes during foetal development, in normal 
tissues and in pathological conditions. 
 
II) To identify factors in tumorigenic processes and in foetal development that induce 
MMP-21 production. 
 
III) To characterize the biological role of MMP-26 and to determine regulatory factors 
for this MMP in skin biology. 
 
IV) To disentangle the roles of MMP-21 and MMP-26 in oesophageal biology and to 
determine their regulatory factors in epithelial tumorigenesis of the oesophagus. 
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4. MATERIALS AND METHODS 
4.1. COMPUTATIONAL SEQUENCE ANALYSIS (I) 
To find new members of the MMP family, a TBLASTN (Altschul et al., 1997) search 
of non-redundant (nr) and high throughput genomic sequences (htgs) databases of the 
GenBank was performed using the peptide string  
XXXFXXXXKWXXXXITYXIXXYXXDLXXXXXDDAFARAFXXWSXVTPLXF
XRXXXXXADIXIXFGXXEHGDGYPFDGKDGLLAHAFXPGXGXXGDXHFDD
DELWXLGXGXVVLFLVAAHEFGHAXGLXHSXXPXALMXPXYXXTXXXXLX
XDDXXGIXXLYGXXP, composed of the catalytic domains of human MMP-2 and -
9 excluding the fibronectin repeats. To predict the coding exons from the genomic 
sequences, we used the Genscan Web Server of Massachusetts Institute of 
Technology (http://genes.mit.edu/GENSCAN.html) (Burge and Karlin, 1998). For 
multiple alignments of nucleotide and amino acid sequences, we used ClustalX and 
BoxShade server 3.21 (http://www.ch.embnet.org/software/BOX_form.html). 
The protein sequence of MMP-21 was used to predict the presence of a signal 
peptide for secretion (http://www.cbs.dtu.dk/services/SignalP/). GeneComposer 
(www.bioinfo.helsinki.fi) was applied to create a hydropathy plot, and on the basis of 
hydrophilic residues in the sequence, we selected a 16-meric peptide for generation of 
antibodies.  
4.2. CELL CULTURES (II-IV) 
Epithelial cell lines were used in our studies on MMP-21 and -26 expression and 
regulation. Human primary KCs were isolated and cultured as described previously 
(Impola et al., 2003). Murine BALB/MK-2 KCs a gift from Dr. Stuart Aaronson 
(National Cancer Institute, Bethesda, MD, USA), were cultured in minimum essential 
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media (MEM) supplemented with 4 ng/ml epidermal growth factor (EGF). 
Immortalized human HaCaT KCs and subclones of increasing malignancy (HaCaT – 
immortalized, A5 – tumourigenic, II-4 – invasive and RT3 – metastatic) were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM) of 1 g/l of glucose supplemented 
with 2 mM L-glutamine, 1 mM sodium pyruvate, 5% foetal calf serum (FCS), 100 
U/ml penicillin and 50 µg/ml streptomycin. The ras-transfected clones were further 
given 200 µg/ml geneticin to maintain their selective pressure (Boukamp et al., 1988). 
MCF7 cells, originally from mammary gland adenocarcinoma, and 293 cells, 
originally from a human foetal kidney, were grown in Eagle’s modified MEM 
supplemented with 10% FCS, 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM 
nonessential amino acids, 100 U/ml penicillin and 50µg/ml streptomycin. A-431 cells, 
originally from an epidermoid carcinoma, were grown in DMEM of 4.5 g/l glucose 
supplemented with 4 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin 
and 50 µg/ml streptomycin. 
KYSE-30 cells, originally from a well-differentiated ESCC (Shimada et al., 
1992), were grown in 1:1 mixture of RPMI 1640 and Ham’s F12 supplemented with 2 
mM L-glutamine, 2% FCS, 100 U/ml penicillin and 50 µg/ml streptomycin. OE21 
cells, originally from a moderately differentiated ESCC (Rockett et al., 1997) were 
grown in RPMI 1640 supplemented with 2 mM L-glutamine, 10% FCS, 100 U/ml 
penicillin and 50 µg/ml streptomycin.  
4.2.1. Cytokines, growth factors, matrices and cultures on chamber slides (II-IV) 
To study the regulation of MMP-21 and MMP-26 expression, equal amounts of cells 
were plated on 6- or 24-well tissue culture plates. The next day, the cells were 
repeatedly washed with phosphate buffered saline (PBS) and incubated in serum-and-
supplement-free medium for 18-24 hours. The cells were then treated with 12-
 34
phorbol-13-myristate-acetate (PMA, 10 ng/ml, Sigma, St. Louis, MO, USA), 
epidermal growth factor (EGF, 10 ng/ml, Sigma), insulin-like growth factor (IGF, 10 
ng/ml, Sigma), tumour necrosis factor alpha (TNF-α, 10 ng/ml, Sigma), transforming 
growth factor beta 1 (TGF-β1, 10 ng/ml, Sigma), interleukin-1 beta (IL-1β, 5 U/ml, 
Sigma), interleukin-6 (IL-6, 1 ng/ml, Sigma), dexamethasone (Dxm, 10-5M, Sigma), 
retinoic acid (RA, 10-6 M, Sigma) or oestrogen (10-6-10-8M, Sigma). To trigger the 
differentiation of primary KCs, the cells were grown in a high Ca2+ (1.8 mM) 
concentration. Stimulation was allowed to proceed for either 24 or 48 hours, after 
which the cells were lysed and total RNA was extracted using a RNeasy Mini-kit 
(Qiagen, Chatsworth, CA, USA) as instructed by the manufacturer. 
4.2.2. Creation of cell lines stably expressing MMP-21 (II) 
To study the localization of MMP-21 in cells, we transfected 293A cells with the full-
length human MMP-21 construct in a pEFIRES-P expression vector (Hobbs et al., 
1998) using a FuGENE 6 transfection reagent (Roche, Indianapolis, IN, USA). The 
next day, the cells were given a fresh complete culture medium, and one day after this 
a medium into which 1 µg/ml puromycin was added to serve as a selective agent. The 
concentration of puromycin was gradually increased up to 160 µg/ml, leaving only the 
fittest cell clones alive. As a negative control, we used the cells transfected with an 
empty pEFIRES-P vector, which were also given up to 160 µg/ml puromycin. 
4.3. EXTRACTION AND ANALYSIS OF RNA 
4.3.1. MMP-21 cloning and sequencing (I) 
Polymerase chain reaction (PCR) analyses of MMP-21 gene expression were done 
using PCR-ready human multiple tissue cDNA (MTC) panels (Clontech, Palo Alto, 
CA, USA). The coding region of MMP-21 was assembled from several overlapping 
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PCR fragments, amplified by gene-specific primers designed for GENSCAN-
predicted exons. The overlapping fragments were amplified by PCR from the first-
strand human placenta cDNA (Ambion, Austin, TX, USA) by reverse transcriptase 
(RT-) PCR using Advantage-2 polymerase (Clontech). For PCR analyses, water was 
always used as a negative control and placenta as a positive control. PCR products 
were run in agarose gel electrophoresis, excised and purified for sequencing or 
subcloning in a TOPO-TA system (Invitrogen, Carlsbad, CA, USA) using a gel 
extraction kit from Qiagen.  
4.3.2. Expression analysis by Northern blotting and PCR panels (I, II) 
Human foetal, human 12-lane and human tumour multiple tissue northern (MTN) 
blots (Clontech) were hybridised with 32P radiolabelled full-length cDNA of MMP-21 
in UltraHyb (Ambion) at 42°C for 18 hours. After washes, the results were visualized 
by autoradiography. 
Human I, II, foetal, tumor, cell line and mouse I MTC panels (Clontech) were 
screened for MMP-21 with primers producing a 1014-bp fragment of MMP-21 gene 
corresponding to nucleotides 725 – 1739 in the coding sequence. The PCR products 
were analysed on agarose gel, and their identity was verified by sequencing. 
4.3.3. Real-time quantitative PCT (TaqMan)(II-IV) 
Total RNA (0.5 µg) was transcribed to cDNA with random hexamers or oligo-dTs 
using TaqMan reverse transcription reagents (Applied Biosystems, Warrington, UK) 
or a SuperScript III first-strand synthesis system (Invitrogen, Carlsbad, CA, USA) 
and then used as a template for TaqMan analyses on an ABI PRISM 7700 Sequence 
Detection System (Applied Biosystems). Primers used for MMP-21 amplification 
were forward primer 5’- GGGATCCATAATGCAACCAAA –3’, reverse primer 5’- 
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ATCCCTCACAGGAGCCATACA –3’ and the probe 5’ – 
CAGACAGGAAAGCAAT – 3’; for MMP-26 amplification forward primer 5’-
ACGTTGGATGGTCAGCTTCAGACACTGGATATA -3’ reverse primer 5’-
ACGTTGGATGGGTACATTATGGAGCTCTGATTC-3’ and the probe 5’-
AGATTGGGCATTCTTTGGGC-3’. For endogenous control, we used the 20x ready-
to-use glyseraldehyde phosphate dehydrogenase (GAPDH) mix containing the 
primers and probe. The probes for MMP-21, -26 and -10 (as a control of the cell 
stimulations with HaCaTs) contained a FAM reporter dye attached to the 5‘ end and a 
TAMRA quencher at the 3‘ end.  
4.4. ANALYSIS OF PROTEINS 
4.4.1. Tissue samples 
The use of archival tissue samples for these studies was approved by the Ethics 
Committees of the Departments of Dermatology, Surgery and Internal Medicine, 
Helsinki University Central Hospital, Helsinki, Finland.  
Foetal samples (I, II). Samples were obtained from Oulu University Hospital. 
Foetal age was estimated by menstrual age and by macroscopic and histological 
examinations. All foetal material used for immunohistochemistry originated from 
medical abortions performed at 7, 8, 10, 12, 14 and 20 weeks of gestation (n=15). 
Skin samples (I- III). These samples included archival specimens of dermatitis 
herpetiformis (n=3), psoriasis (n=3), lichen planus (n=3), seborrhoeic keratosis (n=3), 
normal skin (n=3), acute (n=4), and chronic wounds (n=5), SCC of the skin (n=21, 
grades I-III), BCC of the skin (n=8), and Bowen’s disease (n=3) from the Department 
of Dermatology, Helsinki University Central Hospital.  
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Carcinomas other than skin and oesophageal samples (I, II). Colon (n=4) and 
ovarian carcinomas (n=4) were obtained from the Department of Pathology, Helsinki 
University Central Hospital.  
Mouse tissues (II). Formalin-fixed, paraffin-embedded mouse foetal samples 
included 10-, 13- and 16-day-old embryos (n=15) and respective placentas of NMRI 
mice were from the Haartman Institute, University of Helsinki, Finland. 
Precursor and malignant oesophageal lesions (IV). Formalin-fixed, paraffin-
embedded specimens were collected from 33 patients diagnosed with ESCC at 
Helsinki University Central Hospital. Six tumours were well-differentiated, 19 
moderately differentiated and 8 poorly differentiated ESCCs, according to the World 
Health Organization (WHO) classification (Hamilton and Aaltonen, 2000). In 
addition, 4 nodal metastases and 6 samples representing oesophageal dysplasia were 
stained.  
4.4.2. Immunohistochemistry (I-IV) 
To reveal antigens, the specimens were pretreated as indicated in Table 3, and 
endogenous peroxidase activity was blocked by incubation in 0.3% H2O2 for 30 min. 
Immunostaining was done with the avidin-biotin-peroxidase complex technique 
(StreptABComplex/HRP Duet (Mouse/Rabbit) Kit, Dako A/S, Glostrup, Denmark), 
with the dilutions of the antibodies and pretreatments listed in Table 3. 
Diaminobenzidine (DAB) or aminoethylcarbazole (AEC, for cells cultured on slides) 
was used as a chromogenic substrate and Mayer’s haematoxylin as a counterstain. For 
negative controls, we used normal rabbit IgG, preimmune sera or sera where antigen 
specific sites were blocked with excess antigenic peptide. 
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Table 3: Antibodies and pretreatments used. 
 
Antibodies Source Dilution  / pretreatment 
MMP-7 Oncogene Research Products, Cambridge, MA 1:80 / 95oC water bath 
MMP-9 Research Diagnostics, Flanders, NJ 1:50 
MMP-21 Custom antisera or Triple Point Biologics, Portland, OR (RP3MMP21) 1:250 / trypsin 
MMP-26 Gifts from K. Isaka and C. Lopéz-Otín 1:150 and 1:400 
E-cadherin Zymed Laboratories, South San Francisco, CA 1:200-1:400 
Ki-67 Dako (A047) 1:200 
Laminin-5 γ2 chain Gift from K. Tryggvason 1:800 
p16INK4 BD Pharmingen, San Diego, CA 1:350 
β-catenin Transduction Laboratories, Lexington, KY (C19220) 1:1000 / microwave oven 
 
4.4.3. Antibodies for MMP-21 and Western blotting (I) 
Based on hydropathy plotting, a LYENRNNRTRYGDPIQ peptide was synthesized 
corresponding to amino acids 366-382 in the haemopexin domain and used to raise 
antibodies in rabbits. Peptide synthesis and antibody production were purchased from 
Sigma Genosys (Rehovot, Israel). The specificity of the antibodies was confirmed by 
Western blotting, using a construct of a partial catalytic domain and a complete 
haemopexin domain in a pGEX-6P-3 expression vector. Three hundred nanograms of 
the solubilized fusion protein, produced in Escherichia coli, was diluted 1:1 in 
Laemmli reducing sample buffer (Bio-Rad Laboratories, Hercules, CA, USA) with 
5% β−mercaptoethanol. Denaturated proteins were separated in a 10% 
polyacrylamide gel and transferred to Hybond C-extra (Amersham, Buckinghamshire, 
UK) nitrocellulose membrane using standard protocols. Immunized rabbit antiserum 
was used as a primary antibody and peroxidase-conjugated anti-rabbit IgG as a 
secondary antibody. The protein bands were visualized by chemiluminescence using 
standard protocols. For a negative control, we used peptide-blocked antiserum as the 
primary antibody.  
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5. RESULTS 
5.1. DISCOVERY AND STRUCTURE OF MMP-21 
Search of the high throughput genomic sequences (HTGS) database with our peptide 
string resulted in more than 50 hits, among them AL360176 (accession number for the 
NCBI database of nucleotides), a 156-kb-long genomic sequence on chromosome 10. 
Of the nine predicted coding sequences by GENSCAN analysis, the protein 
translation of one contained characteristic domains of an MMP without a complete 
match to any known MMP. PCR analyses and sequencing confirmed an open reading 
frame for seven exons coding for a signal sequence for secretion, a pro-domain with a 
furin-recognition sequence and classical Cys-switch (PRCGVPD), a catalytic domain 
with a Zn2+-binding site (VAVHEIGHVLGLPH) and a haemopexin domain. MMP-
21 is a poor fit in the MMP subfamilies; it lacks the characteristic amino acids of 
collagenases and stromelysins, the fibronectin repeats of gelatinases and the 
membrane association of membrane-type MMPs (Figure 6). MMP-21 nucleotide 
sequences have deposited in GenBank under accession number AF331526. 
 
Figure 6. Structure of MMP-21 gene (A) and protein (B). 
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5.2. MMP-21 AND -26 IN PHYSIOLOGICAL CONDITIONS (I-III) 
The MMP-21 protein was absent from adult human skin, and wound healing or 
hyperproliferation was unable to induce its expression, as evidenced by our negative 
results in chronic and acute wounds, Bowen’s disease and psoriasis. Cultured human 
and murine KCs, by contrast, were positive for MMP-21 mRNA and protein. 
Inflammatory cells expressed MMP-21; as normal human leukocyte cDNA and 
neutrophils in a dermatitis herpetiformis sample were positive for MMP-21 mRNA 
and protein. 
Expression levels for human MMP-21 were quite low, and by Northern 
blotting, we detected the 2.5-kb transcript only in foetal liver. At 16-32 weeks after 
gestation, the human brains, kidneys and liver expressed MMP-21 mRNA. In addition 
the foetal brains, kidneys, oesophagus, colon, ileum and bronchi expressed MMP-21 
protein epithelially 7-20 weeks after gestation. In mice, MMP-21 mRNA expression 
begins 10 days post-conception, is most abundant by day 13, then declining until day 
16, with parturition occurring on day 21. Foetal murine tissues positive for MMP-21 
protein were the kidneys and the skin. Human and murine placentas were always 
positive for MMP-21 mRNA and protein. 
MMP-26 protein was expressed by KCs of hair follicles in the anagen (hair 
growth) phase in otherwise negative adult human skin. Induction of MMP-26 
occurred in migrating KCs upon acute or chronic wound healing, inflammation or 
microdisruptions of the BM. In acute wounds, MMP-26 co-localized with tumour 
suppressor p16 and with KC migration marker LN5γ2.  
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5.3. DIFFERENTIAL INDUCTION OF MMP-21 AND -26 EXPRESSION DURING MALIGNANT 
TRANSFORMATION OF CUTANEOUS AND OESOPHAGEAL EPITHELIA (I-IV) 
MMP-21 mRNA was expressed in epithelial cancers of the colon, breast and prostate, 
and in the corresponding cell lines. MMP-21 protein was detected in epithelial cancer 
cells and leukocytes surrounding the cancer. The malignant squamous carcinoma cell 
line A-431 was positive for MMP-21 mRNA, but surprisingly, the ras-transformed 
HaCaT subclones revealed no correlation between MMP-21 mRNA levels and 
malignancy potential. 
  
Figure 7. MMP-21 and -26 expression patterns during squamous cell carcinoma progression. 
White spheres depict differentiating epithelial cells and black spheres depict basal, 
undifferentiating cells. Asterisks on cells indicate MMP-21 or -26 expression. 
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Progressing SCCs of the skin and oesophagus were negative for MMP-21 
protein until grade II was reached (Figure 7). Grades II and III SCCs of the skin and 
oesophagus demonstrated MMP-21 protein in invading epithelial cancer cells and 
surrounding neutrophils. A subset of the SCCs had MMP-21-positive islands of well-
differentiated epithelial structures. No association of MMP-21 with MMP-7, 
transactivated β-catenin, proliferation marker Ki-67, KC migration marker LN5γ2 or 
apoptosis marker TUNEL was evident in SCCs, although MMP-21 was often found 
adjacent to apoptotic areas. In BCCs, only the aggressive, sclerosing subtype was 
positive for MMP-21 protein. 
MMP-26 expression was induced, with skin and oesophageal mucosa 
developing malignant behaviour, already in KA of the skin and dysplasia of the 
oesophagus. In grade I and II SCCs, epithelial cancer cells expressed MMP-26 protein 
at the invasive front, but further dedifferentiation of the cancer abolished MMP-26 
protein expression and grade III SCCs were devoid of it (Figure 7). Association of 
MMP-26 with p16 became less evident upon dedifferentiation, as they partially co-
localized in grade I SCC, but in grade II SCC were merely detected in the same areas. 
MMP-26 protein co-localized with LN5γ2, demonstrating that MMP-26 is derived 
from migrating KCs. MMP-26 also co-localized with fragmented elastin in SCC 
samples. The proliferative marker Ki-67 was not associated with MMP-26 protein 
expression in SCCs. 
Only occasional atypical cells of BCCs expressed MMP-26 protein in E-
cadherin-negative areas, but the cancer islands of BCCs were always negative for 
MMP-26.  
To mimic the auxiliary factors involved in tumorigenesis, human KCs were 
treated with seven different growth factors postulated to be important in dermal 
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carcinogenesis (EGF, bFGF, IGF, PMA, TNF−α, TGF−β1 and VEGF; for details, see 
Materials and methods): only TGF−β1 was able to increase MMP-21 mRNA levels 
up to 8-fold. To induce MMP-26 expression from KCs and ESCC cell lines, we 
expanded the selection of growth factors and matrices (see Materials and methods), 
but none of the factors in our system was able to induce MMP-21 mRNA expression 
from ESCC cells or MMP-26 mRNA expression from KCs or ESCC cells. 
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6. DISCUSSION 
6.1. CHARACTERISTICS OF MMP-21 (I, II) 
Most physiological substrates for MMP-21 remain unidentified, despite cleavage of 
α1-anti-trypsin being shown (Marchenko et al., 2003). In our zymographic analyses, 
we were unable to demonstrate gelatinolytic or caseinolytic activities of MMP-21. It 
will be intriguing to see where the physiological substrates place MMP-21, perhaps 
even at the beginning of a proteinolytic cascade regulating breakdown of biological 
structures, should it be able to activate other proteinases or release growth factors or 
novel epitopes from ECM macromolecules. 
6.2. PHYSIOLOGICAL EXPRESSION OF MMP-21 AND -26 (I-III) 
MMP-21 has counterparts in metamorphosing reptiles: XMMP in Xenopus laevis 
(Yang et al., 1997) and CyMMP in Cynopps pyrrhogaster (Suzuki et al., 2001). 
XMMP is undetectable in the blastula stage, induced in the gastrula stage, expressed 
in the neurula stage and then down regulated in the pretailbud stage of the embryo 
(Yang et al., 1997). CyMMP is similarly under tight space and time regulation during 
early newt development (Suzuki et al., 2001). Promoter studies of human and mouse 
MMP-21 have revealed several putative transcription factor binding sites essential in 
foetal development, including Tcf-4, Pax-2, -5, -8 and the Notch-motif (Marchenko et 
al., 2003). Tcf-4 is linked to the wnt-signalling pathway, essential for TGF−β1-
regulated hair follicle development (Li et al., 2003). Pax-2 is involved in kidney 
development, Pax-5 in haematopoiesis and Pax-8 in thyroid development (Chi and 
Epstein, 2002). The Notch-motif participates in the development of the central 
nervous system (del Barco Barrantes et al., 1999). Detailed dissection of developing 
murine organs has further demonstrated MMP-21 mRNA expression in foetal lungs of 
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the mouse (Nuttall et al., 2004). These data and our results suggest that the expression 
pattern of MMP-21 is highly specific to the developmental stage, cell type and tissue 
type in higher vertebrate development. Furthermore, MMP-21 mRNA and protein are 
most prominent in the placenta, suggesting a role in embryo implantation and 
development, as previously shown for many other MMPs. Whether MMP-21 is 
needed for degradation of the provisional matrix, for invasion of cells or for branching 
morphogenesis is currently not known. The epithelial expression pattern makes it 
likely to be excluded from angiogenesis but enables its engagement in the 
development of skin and ductal structures of various organs.  
MMP-21 is expressed in mRNA and protein levels in leukocytes, implying a 
role as a cytokine-regulated effector during innate immune responses or tissue injury. 
MMP-21 is also expressed in low levels in various adult mouse tissues as well as in 
the adult human brain, lung, testis, ovaries and colon, suggesting a role in normal 
tissue homeostasis or turnover. Additional studies with knock-out mice are crucial to 
identify the processes dependent on MMP-21 expression, whether during 
homeostasis, foetal development or cancer progression. 
MMP-26 is absent from the normal intact epidermis but is produced in 
migrating KCs upon skin injury, similar to several other MMPs (see Saarialho-Kere et 
al., 2002). Our positive results for MMP-26 in chronic wounds agree with earlier data 
on MMP-1 and -10, which are also induced in KCs bordering normally healing or 
chronic wounds (Vaalamo et al., 1996). In lichen planus and keratoacanthomas, skin 
disorders with prominent inflammation, MMP-26 protein is detected in basal KCs 
above the inflammatory infiltrate. In psoriasis, another inflammatory skin disorder, 
MMP-26 protein is expressed at the top of dermal papillae, where the BM is though to 
suffer from microdisruptions.  
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MMP-2, -14 (Giannelli et al., 1997; Koshikawa et al., 2005), -8, -13 and -20 
(Pirilä et al., 2003) have been shown to release the pro-migratory γ2 epitope from 
human or murine epidermal LN5, and recent additions to MMPs able to cleave LN5 
include MMP-10 (Krampert et al., 2004) and -19 (Sadowski et al., 2005). MMP-26 
co-localizes with the the LN5γ2-chain in chronic and acute wounds and in well-
differentiated cancers. However, MMP-26 is unable to cleave LN5 (Marchenko et al., 
2001). 
Although MMP-26 has been detected in peripheral leukocytes, lymphocytes 
(Park et al., 2000; Nuttall et al., 2003), fibroblasts and macrophages of other tissues 
than the skin (Bar-Or et al., 2003; Marchenko et al., 2004), our study confirms its 
epithelial origin in the skin and oesophageal mucosa. Furthermore, MMP-26 has 
recently been found in epithelial corneal and conjunctival cells in vivo (Marchenko et 
al., 2004). 
Inability of the growth factors and matrices used to induce MMP-21 and -26 
mRNA expression excludes the participation of some pathways in their regulation. 
TNF−α is unable to increase MMP-21 or -26 mRNA levels from KCs and ESCC 
cells, suggesting that NF−κB is irrelevant in their regulation (Han et al., 2001). PMA 
induces the expression of MMPs from a variety of cells, but HaCaT cells have been 
reported to suffer from a loss of mitogen-activated protein kinase (MAPK)- mediated 
MMP-1 upregulation by PMA, even if EGF-stimulated MMP-1 induction is 
functional (Sudbeck et al. 1999). Primary KCs and ESCC cells are also unable to 
induce MMP-21 or -6 expression upon PMA stimulation, reflecting the independence 
of expression from PMA stimulation. HUVEC, MRC-5 and PC3 cells have previously 
been shown to induce MMP-26 expression upon PMA stimulation (Nuttall et al., 
2003). Recently, MMP-26 expression was suggested to be oestrogen-dependent, as its 
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promoter contains an oestrogen-responsive element and MMP-26 is expressed by 
many oestrogen-dependent cell lines (Li et al., 2004). In our system, addition of 
oestrogen at physiological levels was unable to upregulate MMP-26 in ESCC cells. It 
is possible that in KCs and ESCC cells at least two stimulators, hypoxia, certain 
integrin interactions or co-culture studies employing fibroblasts, macrophages, 
neutrophils or other stromal components are needed for upregulation of MMP-21 and 
-26 or that actual in vivo events with cell-cell and cell-matrix interactions modifying 
MMP expression can not be recapitulated in simplistic cell culture models.  
6.3. EXPRESSION OF MMP-21 AND -26 IN KERATINOCYTE-DERIVED CANCERS OF THE SKIN 
AND OESOPHAGUS (II-IV) 
The Wnt- signalling pathway is commonly activated in epithelial carcinogenesis, 
often involving a loss of cell-cell contacts via E-cadherin and catenins. β−catenin then 
accumulates in the cytoplasm and in the nucleus, where it acts as a regulatory element 
for transcription of several genes (Seidensticker et al., 2000). The presence of the Tcf-
4 binding site in the promoter of MMP-21 suggests its regulation to coincide with 
transactivation of β−catenin, although we were unable to detect an association 
between accumulated nuclear or cytoplasmic β−catenin and MMP-21 protein in skin, 
colon or oesophageal cancers. In ESCC, MMP-7 expression, together with nuclear 
β−catenin expression, correlates with tumour invasion to neighbouring tissues (Saeki 
et al., 2002), but in cutaneous and oesophageal SCCs, MMP-7 and -21 proteins were 
not co-localized in our material. 
The induction of MMP-21 mRNA expression in KCs by TGF−β1 is 
intriguing, as TGF−β1 either up- or downregulates several MMPs, depending on cell 
type (Gold et al., 2000). TGF−β1 increases the mRNA levels of MMP-1, -10 and -9 in 
primary KCs (Rechardt et al., 2000; Han et al., 2001). In primary and immortalized 
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KCs, TGF−β1 inhibits growth and proliferation (Gold et al., 2000), whereas these 
effects disappear in the more malignant A-431 cells (Lange et al., 1999). Indeed, 
TGF−β1 has been shown to have a double role in epithelial tumorigenesis; at early 
stages, it induces an epithelial to mesenchymal transition (EMT) (Bhowmick et al., 
2001), but it may also act as a tumour suppressor and, with malignant progression, it 
may promote tumorigenesis (Lange et al., 1999). Macrophages are also an important 
source for TGF−β1, which in turn stimulates MMP-production from tumour or 
stromal cells to aid in the invasive processes. Interestingly, increased expression of 
TGF−β isoforms has been observed in a variety of human carcinomas, including 
colon, breast and prostate cancers (Gorsch et al., 1992; Truong et al., 1993), with all 
tumours also expressing MMP-21. 
The inability of TGF−β1 to increase expression levels of MMP-21 mRNA in 
ESCC cells may indicate the loss of TGF−β1 control of more malignant epithelial 
cells or that at the more advenaced stages, MMP-21 is no longer expressed in the 
cells. The induction of MMP-21 expression occurs early in melanocyte 
transformation, it disappears from the most malignant tumours and there is no 
correlation between MMP-21 expression and the existence of micrometastases 
(Kuivanen et al., 2005). MMP-21 mRNA levels are unaltered between malignant and 
non-malignant samples of the prostate (Riddick et al., 2005). Using foetal and cancer 
cell lines of low and high invasive potential, we created three cell lines that stably 
over-express MMP-21, changes in the invasive capacities and malignant properties of 
which remain to be studied. 
MMP-21 was detected in neutrophils in skin and oesophageal SCCs. However, 
discrepant data exist on the role of neutrophils proteases in cancer; while loss of 
neutrophil MMP-8 confers increased susceptibility to skin tumours in mice (Balbín et 
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al., 2003), neutrophil MMP-9 promotes skin carcinogenesis (Coussens et al., 2000). 
Whether MMP-21 is a cause for or a result of inflammation and contact with the 
cancer remains to be elucidated; not all neutrophils in contact with cancer expressed 
MMP-21 in our material. MMP-21 contains a furin activation sequence, which makes 
furin inhibition a potential means of eliminating MMP-21 activity. Indeed, 
localization of furin at the invasive front of SCCs strongly resembles localization of 
MMP-21 (Lopéz De Cicco et al., 2004). 
While our study was underway, Yamamoto et al. (2003) showed that MMP-26 
expression correlated strongly with invasion depth, lymph node and distant metastasis 
and advanced TNM stage in ESCC. The essential role of MMP-26 in oesophageal 
tumorigenesis was further demonstrated to arise from activation of MMP-9. We also 
observed the involvement of MMP-26 in the tumorigenic processes, especially in 
early invasion through the BM and in the association with inflammation and apoptotic 
tumour islets. Loss of heterogeneity (LOH) for p16 is a frequent event in SCC 
progression (Boukamp, 2005). In the skin either inflammation or atypia was sufficient 
for MMP-26 induction in KCs, and MMP-26 was associated with early cutaneous 
tumorigenesis, often co-localizing with tumour suppressor p16. In well-differentiated 
SCCs of the skin and oesophagus, the expression patterns of MMP-26 resembled that 
of p16, and the disappearance of MMP-26 from the dedifferentiated, aggressive SCCs 
suggests the importance of MMP-26 in early cutaneous and oesophageal 
tumorigenesis, whereas other MMP members promote the invasive phenomena. Thus, 
lack of MMP-26 could be a marker for aggressive growth, since, like the novel MMPs 
-19 and -28, it is expressed already in pre-malignant lesions and disappears from the 
most dedifferentiated SCCs (Saarialho-Kere et al., 2002; Impola et al., 2003). This 
agrees with previous results on oral SCC (Impola et al., 2004) and with the data of 
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Zhao et al. (2004), who found higher levels of MMP-26 in ductal carcinoma in situ 
than in infiltrating breast carcinoma, suggesting that once the BM has been breached 
the cancer cells become less dependent on the activity of MMP-26. Furthermore, the 
tumour-to-normal tissue ratio of MMP-26 in both kidney tissue and endometrial 
carcinoma is considerably different from that of MMPs classically associated with 
malignancy, and MMP-26 is detected in many carcinomas and the corresponding 
normal tissues (Isaka et al., 2003; Marchenko et al., 2004). However, recent data 
show that epithelial and stromal cells of prostate cancers express MMP-26 and its 
upregulation correlates strongly with the Gleason score indicating aggressiveness of 
the tumour (Riddick et al., 2005). 
In conclusion, our findings reveal that MMP-26 is important in the early steps 
of cutaneous and oesophageal tumorigenesis, while MMP-21 contributes to invasion, 
based on its presence in the invasion front. MMP-26 could serve as a marker for 
incipient invasion, aiding in identifying patients in need of more radical treatment for 
dysplastic and premalignant changes in the cutaneous and oesophageal epithelia.  
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7. CONCLUSIONS AND FUTURE PROSPECTS 
In tissue homeostasis, the balance between production and breakdown of the 
extracellular matrix is crucial. ECM remodelling requires that old structures be 
degraded before new ones are built. In biological situations, one group of molecular 
bulldozers is the MMPs. Processes demanding extensive remodelling, such as foetal 
development or female reproductive cycles, are characterized by high expression 
levels of MMPs and TIMPs. Sometimes tissue degradation is extensive without 
apparent reason and can cause or assist in creating and maintaining pathological 
conditions, such as chronic wounds, rheumatoid arthritis, atherosclerosis or cancer. 
Numerous studies have proven MMPs to be important players in these processes. 
Here, we introduced a novel member of the MMP family of proteolytic enzymes, 
MMP-21, and examined its expression, along with another novel MMP, MMP-26, in 
SCCs of the skin and oesophagus. Furthermore, we studied the role of MMP-21 in 
human and murine development, and detected a restricted pattern of protein 
expression in selected epithelial structures of the kidney, skin and lungs. Expression 
of MMP-21 mRNA in cultured KCs was induced in response to TGF−β1. 
MMP-21 contains all of the characteristic features of MMPs: a signal 
sequence for secretion, a pro-domain with a Cys-switch sequence for preservation of 
latency prior to activation, a furin-cleavage site, catalytic domain with binding sites 
for the Zn2+ ion needed for activity and the four-leafed haemopexin domain needed 
for substrate recognition and interactions with TIMPs. MMP-21 mRNA was 
expressed in human and murine adult and foetal tissues and in human cancer cell lines 
of epithelial origin. MMP-21 protein was detected in developing epithelial cells, in 
neutrophils and in aggressive subtypes of squamous and basal cell cancers. Normal 
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skin was devoid of MMP-21 protein both in adult humans and mice. We found no co-
localization of MMP-21 with transactivated β−catenin or MMP-7 in cutaneous or 
oesophageal SCCs. 
In normally healing wounds and in cutaneous SCCs of grades I and II, the 
migrating LN5γ2 positive KCs and the KCs of the epithelial tip of chronic wounds 
expressed MMP-26 protein, whereas MMP-21 was not associated with wound repair 
or KC migration. Both normal and developing skin was negative for MMP-26 protein, 
and it never co-localized with the proliferation marker Ki-67 in SCCs of the skin or 
oesophagus or in BCCs of the skin. 
MMP-26 can activate MMP-9, and they were found in the same regions in 
normal wounds and cutaneous SCCs, but adjacent to each other rather than directly 
co-localizing. MMP-26 was induced by KC atypia and by BM microdisruptions even 
in benign skin lesions. It was associated with early carcinogenesis but disappeared 
from more aggressive tumours. MMP-26 mRNA was expressed only at low levels in 
cultured cells of the skin and oesophagus. 
In conclusion, this study introduced the last member of the MMP-family, 
MMP-21, and its mRNA and protein expression in transformed epithelial cells of the 
skin and oesophagus. We showed for the first time that MMP-21 mRNA is 
upregulated in KCs by TGF−β1. Oesophageal SCC cell lines had lost the ability to 
respond to TGF−β1 by upregulating MMP-21 mRNA expression. MMP-21 is 
expressed at mRNA and protein levels during human and murine foetal development. 
We also illustrated for the first time the role of MMP-26 in skin biology; it is present 
in migrating KCs, co-localizes with tumour suppressor p16 and disappears from SCCs 
along with dedifferentiation. 
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Tumours select their locations based on the “seed and soil” hypothesis. The 
microenvironment must be optimal for cancerous growth to proceed, for blood supply 
to function and for dissection of tumour cells and their passage and attachment to 
distant sites to form metastases. MMPs do the work of processing the ECM and 
activating cancer-promoting cytokines, but, as the processes work in favour of all 
steps in the tumourigenic process, they also have adverse roles and hinder all phases 
of the transformation and subsequent malignant processes. To precisely address the 
significance of a given protein in epithelial biology, a transgenic gain or loss of 
function animal model would be useful. To our knowledge, an MMP-21-null or over-
expressing mouse does not yet exist, and since MMP-26 lacks the murine counterpart, 
it is unlikely to be a target of knock-out or knock-in experiments. However, because 
human and mouse systems are not identical, care needs to be taken when interpreting 
the necessity of a protease in humans based on the results of its deletion in mice. The 
hallmarks of malignancy, the major causes for cancer-related mortality and morbidity 
and the main impediments to improved cures are invasion and metastasis. Regardless 
of the regulatory mechanisms, it is essential to determine whether MMP expression 
can be a predictive marker for metastasis, identify a target for therapeutic intervention 
or aid in choosing adjuvant therapy for patients needing a more radical treatment for 
cancer. 
 54
8. ACKNOWLEDGEMENTS 
These studies were performed at the Department  of Dermatology, Helsinki 
University Central Hospital, at the Department of Medical Genetics, and at 
Biomedicum Helsinki during 2000-2005. The Head of the Skin and Allergy Hospital, 
Professor Annamari Ranki, is warmly thanked for providing excellent research 
facilities within Biomedicum Helsinki and the Hospital.  
Docents Kaisa Tasanen and Ylermi Soini, the official reviewers of the 
thesis, are gratefully acknowledged for constructive criticism and insightful comments 
on the manuscript.  
My supervisor, Professor Ulpu Saarialho-Kere, is acknowledged for 
introducing me to the world of MMPs and for consistently pushing me, ensuring this 
thesis to be completed. Juha Kere, Jouko Lohi and Hannes Lohi are warmly thanked 
for invaluable instruction in cloning novel members of existing gene families. I am 
also indebted to Jouko and Hannes as well as to Outi Elomaa for practical help, for 
sound advice and for letting me release accumulated steam every now and then.  
Carol Ann Pelli is warmly thanked for revising the English language of this thesis. 
I warmly thank everyone in our lab: Erja, Ullis, Alli, Mikko, Sari, Netta 
and Sakari. Our team has been strong, with the philosophy of the musketeers “all for 
one and one for all”. I hope that you have had as much fun with me as I have had with 
you! To the original Biomedicum team and the supplements: Harri, Veli-Matti, 
Samuli, Paula, Harri M., Marja, Susanna, Kati, Kirsi, Marjut, Laura, Tiina, Ville, 
Jatta, Otto and Olli: time spent with you inside and outside the lab has always been 
fun, when not even hilarious. I’ll try to keep in mind that a policeman is always a 
friend, Samuli! Anja, Ritva and Jaana are thanked for keeping the laboratory going 
 55
and the strong coffee brewing.  Members of Juha’s group, Nina, Minna, Siru, Kata, 
Outi, Inkeri, Siv, Riitta and Ranja: thank you for lending me a hand or an instrument 
whenever I needed one. Hannu is especially thanked for keeping my computer in 
great shape at all times. Ladies in the histopathology team: time spent in the DNA lab 
has never been lonely, thanks to you. Kaija deserves special thanks for her mule-like 
activities in carrying this and that between the hospital and Biomedicum. Päivi, 
Leena, Essi and Charlotta in City-Lab and Riitta in Yliopistokirjakauppa are thanked 
for fulfilling all of my daily needs, whether it was a question of candy, a chat, advice 
or even a actual job! 
My dear friends are thanked for just letting me be me: Minna and Krisu 
for keeping me in shape and pushing me to the gym ever so often, and the families 
Hirvenkari, Helle, Impola and Majewski for getting us out of the house both during 
the building project and during this thesis. 
Viimeiseksi suurimmat kiitokset kuuluvat elämäni isoimmalle ja 
tärkeimmälle projektille, perheelle: Juha, Paula ja Venla. Arki kanssanne auttoi 
jaksamaan välillä raskaankin väitöskirjaprosessin loppuun asti. Vanhempani Terttu ja 
Markku ansaitsevat kiitokset vankkumattomasta uskostaan minuun. Appivanhempiani 
Elliä ja Masaa tahdon kiittää koko prosessin mahdollistamisesta. Olette hoitaneet 
tyttöjä aina tarvittaessa. Kiitos. 
This study was financially supported by the Academy of Finland, the Sigrid 
Juselius Foundation, Helsinki University Research Funds (EVO), the Finnish Cancer 
Research Foundation and Finska Läkaresällskapet and by personal grants from the 
Finnish Cultural Foundation, the Ida Montin Foundation, the Paulo Foundation, the 
Finnish Concordia Fund, the Biomedicum Helsinki Foundation and Biotop Oy. 
 
Helsinki, 25.10.2005 
 56
9. REFERENCES 
Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. 
Gappeed BLAST and PSI-BLAST: a new generation of protein database search 
programs. Nucleic Acids Res 25, 3389-3402, 1997. 
 
Balbín M, Fueyo A, Tester AM, Pendás AM, Pitiot AS, Astudillo A, Overall CM, 
Shapiro SD, Lopéz-Otín C. Loss of collagenase-2 confers increased skin tumor 
susceptibility to male mice. Nat Genet 35, 252-257, 2003. 
 
del Barco Barrantes I, Elia AJ, Wünsch K, de Angelis MH, Mak TW, Rossant J, 
Conlon RA, Gossler A, de la Pompa JL. Interaction between Notch signalling and 
Lunatic fringe during somite boundary formation in the mouse. Curr Biol 9, 470–480, 
1999. 
 
Bar-Or A, Nuttall RK, Duddy M, Alter A, Kim HJ, Ifergan I, Pennington CJ, 
Bourgoin P, Edwards DR, Yong VW. Analyses of all matrix metalloproteinase 
members in leukocytes emphasize monocytes as major inflammatory mediators in 
multiple sclerosis. Brain 126, 1-12, 2003. 
 
Beavon IR. The E-cadherin-catenin complex in tumour metastasis: structure, function 
and regulation. Eur J Cancer 36, 1607-1620, 2000. 
 
Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe 
P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic 
switch during carcinogenesis. Nat Cell Biol 10, 737-744, 2000. 
 
Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga 
CL, Moses HL. Transforming growth factor-beta1 mediates epithelial to 
mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol 
Cell 12, 27-36, 2001. 
 
Björklund M, Heikkila P, Koivunen E. Peptide inhibition of catalytic and noncatalytic 
activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion. J 
Biol Chem 279, 29589, 29597, 2004. 
 
Boukamp P. Non-melanoma skin cancer: what drives tumor development and 
progression. Carcinogenesis 26, 1657-1667, 2005.  
 
Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. 
Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte 
cell line. J Cell Biol 106, 761-771, 1988. 
 
Bullard KM, Lund L, Mudgett JS, Mellin TN, Hunt TK, Murphy B, Ronan J, Werb Z, 
Banda MJ. Impaired wound contraction in stromelysin-1-deficient mice. Ann Surg 
230, 260-265, 1999. 
 
 57
Burge CB, Karlin S. Finding the genes in genomic DNA. Curr Opin Struct Biol 8, 
346-354, 1998. 
 
Bäckvall H, Asplund A, Gustafsson A, Sivertsson Å, Lundeberg J, Ponten F. Genetic 
tumor archeology: microdissection genetic heterogeneity in squamous and basal cell 
carcinoma. Mut Res 571, 65-79, 2005. 
 
Caterina JJ, Skobe Z, Shi J, Ding Y, Simmer JP, Birkedal-Hansen H, Bartlett JD. 
Enamelysin (matrix metalloproteinase 20)-deficient mice display an amelogenesis 
imperfecta phenotype. J Biol Chem 277, 49598-495604, 2002. 
 
Chi N, Epstein JA. Getting your pax straight: Pax proteins in development and 
disease. Trends Genet 18, 41–47, 2002. 
 
de Coignac AB, Elson G, Delneste Y, Magistrelli G, Jeannin P, Aubry JP, Berthier O, 
Schmitt D, Bonnefoy JY, Gauchat JF. Cloning of MMP-26. A novel matrilysin-like 
proteinase. Eur J Biochem 267, 3323-3329, 2000. 
 
Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-
derived cells contributes to skin carcinogenesis. Cell 103, 481-490, 2000. 
 
D'Armiento J, DiColandrea T, Dalal SS, Okada Y, Huang MT, Conney AH, Chada K. 
Collagenase expression in transgenic mouse skin causes hyperkeratosis and 
acanthosis and increases susceptibility to tumorigenesis. Mol Cell Biol 15, 5732-5739, 
1995. 
 
Dumas V, Kanitakis J, Charvat S, Euvrard S, Faure M, Claudy A. Expression of 
basement membrane antigens and matrix metalloproteinases 2 and 9 in cutaneous 
basal and squamous cell carcinomas. Anticancer Res 19, 2929–2938, 1999. 
 
Dunsmore SE, Saarialho-Kere UK, Roby JD, Wilson CL, Matrisian LM, Welgus HG, 
Parks WC. Matrilysin expression and function in airway epithelium. J Clin Invest 
102, 1321-1331, 1998. 
 
Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma 
generation and wound healing. N Engl J Med 315, 1650-1659, 1986. 
 
Egeblad M, Werb Z. New functions for matrix metalloproteinases in cancer 
progression. Nat Rev Cancer 2, 161-174, 2002. 
 
Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 349: 2241-2252, 2003. 
 
Etoh T, Inoue H, Yoshikawa Y, Barnard GF, Kitano S, Mori M. Increased expression 
of collagenase-3 (MMP-13) and MT1-MMP in oesophageal cancer is related to 
cancer aggressiveness. Gut 47, 50-56, 2000. 
 
Fata JE, Leco KJ, Voura EB, Yu HY, Waterhouse P, Murphy G, Moorehead RA, 
Khokha R. Accelerated apoptosis in the Timp-3-deficient mammary gland. J Clin 
Invest 108, 831-841, 2001. 
 
 58
Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis 
revisited. Nat Rev Cancer 3, 1-6, 2002. 
 
Ghohestani RF, Li K, Rousselle P, Uitto J. Molecular organization of the cutaneous 
basement membrane zone. Clin Dermatol 19, 551-562, 2001. 
 
Giannelli G, Marzillier JF, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction 
of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 277, 
225-228, 1997. 
 
Gill SE, Pape MC, Khokha R, Watson AJ, Leco KJ. A null mutation for tissue 
inhibitor of metalloproteinases-3 (Timp-3) impairs murine bronchiole branching 
morphogenesis. Dev Biol 261, 313-323, 2003. 
 
Gold LI, Jussila T, Fusenig NE, Stenbäck F. TGF-β isoforms are differently expressed 
in increasing malignant grades of HaCaT keratinocytes, suggesting separate roles in 
skin carcinogenesis. J Pathol 190, 579–588, 2000. 
 
Gorsch SF, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immunohistochemical 
staining for transforming growth factor−β1 associates with disease progression in 
human breast cancer. Cancer Res 52, 6949–6952, 1992. 
 
Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor 
suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54, 
4855-4878, 1994. 
 
Gross J, Lapière CM. Collagenolytic activity in amphibian tissues: a tissue culture 
assay. Proc Natl Acad Sci USA 48, 1014–1022, 1962. 
 
Ha HY, Moon HB, Nam MS, Lee JW, Ryoo ZY, Lee TH, Lee KK, So BJ, Sato H, 
Seiki M, Yu DY. Overexpression of membrane-type matrix metalloproteinase-1 gene 
induces mammary gland abnormalities and adenocarcinoma in transgenic mice. 
Cancer Res 61, 984-990, 2001. 
 
Hamilton SR, Aaltonen LA. (Eds.): World Health Organization Classification of 
Tumours. Pathology and Genetics of Tumours of the Digestive System. IARC Press: 
Lyon 2000. 
 
Han Y-P, Tuan T-L, Hughes M, Wu H, Garner WL. Transforming growth factor−β- 
and tumor necrosis factor−α-mediated induction and proteolytic activation of MMP-9 
in human skin. J Biol Chem 276, 22341–22350, 2001. 
 
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100, 57-70, 2000. 
 
Hatz RA, Niedner R, Vanscheidt W, Westerhof W. Physiology of wound healing. In: 
Wound healing and wound management. Springer Verlag, Heidelberg, Germany, 
1994, pp. 1-16. 
 
 59
Hautamäki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for 
macrophage elastase for cigarette smoke-induced emphysema in mice. Science 277, 
2002-2004, 1997. 
 
Hieta N, Impola U, Lopéz-Otín C, Saarialho-Kere U, Kähäri VM. Matrix 
metalloproteinase-19 expression in dermal wounds and by fibroblasts in culture. J 
Invest Dermatol 121, 997-1004, 2003.  
 
Hobbs S, Jitrapakdee S, Wallace JC. Development of a bicistronic vector driven by 
the human polypeptide chain elongation factor 1α promoter for creation of stable 
mammalian cell lines that express very high levels of recombinant proteins. Biochem 
Biophys Res Commun 252, 368–372, 1998. 
 
Hojilla CV, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue 
inhibitors direct cell fate during cancer development. Br J Cancer 89, 1817-1821, 
2003. 
 
Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani 
M, Robey PG, Poole AR, Pidoux I, Ward JM, Birkedal-Hansen H. MT1-MMP 
deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease 
due to inadequate collagen turnover. Cell 99, 81-92, 1999. 
 
Hotary KB, Yana I, Sabeh F, Li XY, Holmbeck K, Birkedal-Hansen H, Allen ED, 
Hiraoka N, Weiss SJ. Matrix metalloproteinases (MMPs) regulate fibrin-invasive 
activity via MT1-MMP-dependent and -independent processes. J Exp Med 195, 295-
308, 2002. 
  
Impola U, Uitto VJ, Hietanen J, Hakkinen L, Zhang L, Larjava H, Saarialho-Kere U. 
Differential expression of matrilysin-1 (MMP-7), 92 kDa gelatinase (MMP-9) and 
metalloelastase (MMP-12) in oral verrucous and squamous cell cancer. J Pathol 202, 
14–22, 2004. 
 
Impola U, Toriseva M, Suomela S, Jeskanen L, Hieta N, Jahkola T, Grenman R, 
Kähäri V-M, Saarialho-Kere U. Matrix metalloproteinase-19 is expressed by 
proliferating epithelium but disappears with neoplastic dedifferentation. Int J Cancer 
103, 709–716, 2003. 
 
Inada M, Wang Y, Byrne MH, Rahman MU, Miyaura C, Lopez-Otin C, Krane SM. 
Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage 
and in endochondral ossification. Proc Natl Acad Sci USA 101, 17192-17197, 2004. 
 
Isaka K, Nishi H, Nakai H, Nakada T, Li YF, Ebihara Y, Takayama M. Matrix 
metalloproteinase-26 is expressed in human endometrium but not in endometrial 
carcinoma. Cancer 97, 79-89, 2003. 
 
Itoh T, Tanioka M, Matsuda H, Nishimoto H, Yoshioka T, Suzuki R, Uehira M. 
Experimental metastasis is suppressed in MMP-9 deficient mice. Clin Exp Metastasis 
17, 177-181, 1999. 
 
 60
Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced 
angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 58, 
1048-1051, 1998. 
 
Johansson N, Kähäri VM. Matrix metalloproteinases in squamous cell carcinoma. 
Histol Histopathology 15, 225-237, 2000. 
 
Kalluri R. Basement membranes: structure, assembly and role in tumour 
angiogenesis. Nat Rev Cancer 3, 422-433, 2003. 
 
Kane CL, Keenh CA, Smithberger E, Glass LF. Histopathology of cutaneous 
squamous cell carcinoma and its variants. Sem Cutan Med Surg 23, 54-61, 2004. 
 
Kerkelä E, Saarialho-Kere U. Matrix metalloproteinases in tumor progression: focus 
on basal and squamous cell skin cancer. Exp Dermatol 12, 109-125, 2003. 
 
Kerkelä E, Ala-aho R, Lohi J, Grénman R, Kähäri VM, Saarialho-Kere U. Differential 
patterns of stromelysin-2 (MMP-10) and MT1-MMP (MMP-14) expression in 
epithelial skin cancers. Br J Cancer 84, 659-669, 2001. 
 
Kerkelä E, Ala-aho R, Jeskanen L, Rechardt O, Grénman R, Shapiro SD, Kähäri VM, 
Saarialho-Kere U. Expression of human macrophage metalloelastase (MMP-12) by 
tumor cells in skin cancer. J Invest Dermatol 114, 1113-1119, 2000. 
 
Kim KH, Burkhart K, Chen P, Frevert CW, Randolph-Habecker J, Hackman RC, 
Soloway PD, Madtes DK. Tissue inhibitor of metalloproteinase-1 deficiency 
amplifies acute lung injury in bleomycin-exposed mice. Am J Respir Cell Mol Biol 
33, 271-279, 2005. 
 
Koshikawa N, Minegishi T, Sharabi A, Quaranta V, Seiki M. Membrane-type matrix 
metalloproteinase-1 (MT1-MMP) is a processing enzyme for human laminin gamma 
2 chain. J Biol Chem 250, 88-93, 2005. 
 
Krampert M, Bloch W, Sasaki T, Bugnon P, Rülicke T, Wolf E, Aumailley M, Parks 
WC, Werner S. Activities of the matrix metalloproteinase stromelysin-2 (MMP-10) in 
matrix degradation and keratinocyte organization in wounded skin. Mol Biol Cell 15, 
5242-5254, 2004. 
 
Kuivanen T, Ahokas K, Virolainen S, Jahkola T, Hölttä E, Saksela O, Saarialho-Kere 
U. MMP-21, unlike MMP-26, is induced at early stages of melanoma progression, but 
disappears with more aggressive phenotype. Virchows Arch 20, 1-7, 2005. 
 
Lange D, Persson U, Wollina U, ten Dijke P, Castelli E, Heldin C-H, Funa K. 
Expression of TGF−β related Smad proteins in human epithelial skin tumors. Int J 
Oncol 14, 1049–1056, 1999. 
 
Launoy G, Milan CH, Faivre J, Pienkovski P, Milan CI, Gignoux M. Alcohol, tobacco 
and oesophageal cancer: effects of the duration of consumption, mean intake and 
current and former consumption. Br J Cancer 75: 1389-1396, 1997.  
 
 61
Leco KJ, Waterhouse P, Sanchez OH, Gowing KL, Poole AR, Wakeham A, Mak TW, 
Khokha R. Spontaneous air space enlargement in the lungs of mice lacking tissue 
inhibitor of metalloproteinases-3 (TIMP-3). J Clin Invest 108, 817-829, 2001. 
 
Li AG, Koster MI, Wang XJ (2003). Roles of TGF signaling in epidermal/appendage 
development. Cytokine Growth Factor Rev 14, 99–111, 2003. 
 
Li G, Ho VC, Berean K, Tron VA. Ultraviolet radiation induction of squamous cell 
carcinomas in p53 transgenic mice. Cancer Res 55, 2070-2074, 1995. 
 
Li W, Savinov AY, Rozanov DV, Golubkov VS, Hedayat H, Postnova TI, Golubkova 
NV, Linli Y, Krajewski S, Strongin AY. Matrix metalloproteinase-26 is associated 
with estrogen-dependent malignancies and targets alpha1-antitrypsin serpin. Cancer 
Res 64, 8657-8665, 2004. 
 
Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential 
correlates with enzymatic degradation of basement membrane collagen. Nature 284, 
67-68, 1980. 
 
Lohi J, Wilson CL, Roby JD, Parks WC. Epilysin, a novel human matrix 
metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to 
injury. J Biol Chem 276, 10134-10144, 2001. 
 
Lopéz de Cicco R, Bassi DE, Zucker S, Seidah NG, Klein-Szanto AJP. Human 
carcinoma cell growth and invasiveness is impaired by the propeptide of the 
ubiquitous proprotein convertase furin. Cancer Res 65, 4162-4171, 2005. 
 
Lopéz-Otín C, Overall CM. Protease degradomics: a new challenge for proteomics. 
Nat Rev Mol Cell Biol 3, 509-519, 2002. 
 
Mandard AM, Marnay J, Gignoux M, Segol P, Blanc L, Ollivier JM, Borel B, 
Mandard JC. Cancer of the esophagus and associated lesions: detailed pathologic 
study of 100 esophagectomy specimens. Hum Pathol 15, 660-669, 1984. 
 
Marchenko GN, Marchenko ND, Strongin AY. The human and mouse matrix 
metalloproteinase MMP-21: The structure and the regulation of the gene and the 
protein. Biochem J 372,503–515, 2003.  
 
Marchenko GN, Marchenko ND, Leng J, Strongin AY. Promoter characterization of 
the novel human matrix metalloproteinase-26 gene: regulation by the T-cell factor-4 
implies specific expression of the gene in cancer cells of epithelial origin. Biochem J 
363, 253-262, 2002. 
 
Marchenko GN, Ratnikov BI, Rozanov DV, Dodzik A, Deryugina EI, Strongin AY. 
Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely 
expressed in cancer cells of epithelial origin. Biochem J 356, 705-718, 2001.  
 
Marchenko ND, Marchenko GN, Weinreb RN, Lindsey JD, Kyshtoobayeva A, 
Crawford HC, Strongin AY. β−catenin regulates the gene of MMP-26, a novel matrix 
 62
metalloproteinase expressed both in carcinomas and normal epithelial cells. Int J 
Biochem Cell Biol 36, 942–956, 2004. 
 
Martin DC, Ruther U, Sanchez-Sweatman OH, Orr FW, Khokha R. Inhibition of 
SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice. 
Oncogene 13, 569-576, 1996. 
 
Martin P and Parkhurst SM. Parallels between tissue repair and embryo 
morphogenesis. Development 131, 3021-3034, 2004. 
 
Martin P. Wound healing – aiming for perfect skin regeneration. Science 276, 75-81, 
1997. 
 
Masson R, Lefebvre O, Noël A, El fahime M, Chenard M-P, Wendling C, Kebers F, 
LeMeur M, Dierich A, Foidart J-M, Basset P, Rio M-C. In vivo evidence that the 
stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell 
malignancy. J Cell Biol 140, 1535-1541, 1998. 
 
McCawley LJ, Crawford HC, King LE Jr, Mudgett J, Matrisian LM. A protective role 
for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res 64, 6965-
6972, 2004.  
 
McGrath JA, Eady RAJ, Pope FM. Anatomy and organization of human skin. In: 
Rook’s textbook of dermatology. 7th Ed. Blackwell Science Ltd, 2004. Turin, Italy. 
 
Medina OP, Kairemo K, Valtanen H, Kangasniemi A, Kaukinen S, Ahonen I, Permi 
P, Annila A, Sneck M, Holopainen JM, Karonen SL, Kinnunen PK, Koivunen E. 
Radionuclide imaging of tumor xenografts in mice using a gelatinase-targeting 
peptide. Anticancer Res 25, 33-42, 2005. 
 
Mortier L, Marchetti P, Delaporte E, Martin de Lassalle E, Thomas P, Piette P, 
Formstecher P, Polakowska R, Danze PM. Progression of actinic keratosis to 
squamous cell carcinoma of the skin correlates with deletion of the 9p21 region 
encoding the p16(INK4a) tumor suppressor. Cancer Lett 176, 205-214, 2002. 
 
Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr 
Opin Cell Biol 16, 558-564, 2004. 
 
Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in 
cancer. Nat Rev Cancer 4, 839-849, 2004. 
 
Nemes Z, Steinert PM. Bricks and mortar of the epidermal barrier. Exp Mol Med 31, 
5-19, 1999. 
 
Noda M, Oh J, Takahashi R, Kondo S, Kitayama H, Takahashi C. RECK: a novel 
suppressor of malignancy linking oncogenic signaling to extracellular matrix 
remodeling. Cancer Metastasis Rev 22, 167-175, 2003. 
 
 63
Nothnick WB. Disruption of the Tissue Inhibitor of Metalloproteinase-1 Gene Results 
in Altered Reproductive Cyclicity and Uterine Morphology in Reproductive-Age 
Female Mice. Biol Reprod 63, 905-912, 2000. 
 
Nuttall RK, Sampieri CL, Pennington CJ, Gill SE, Schultz GA, Edwards DR. 
Expression analysis of the entire MMP and TIMP gene families during mouse tissue 
development. FEBS Letters 563, 129-134, 2004. 
 
Nuttall RK, Pennington CJ, Taplin J, Wheal A, Yong VW, Forsyth PA, Edwards DR. 
Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling 
proteases and inhibitors in human cancer cells. Mol Cancer Res 1, 333-345, 2003. 
 
Oikarinen A and Tasanen-Määttä K. Ihon rakenne, tehtävät ja toiminta. In: Ihotaudit. 
1st Ed. Duodecim, 2003, Helsinki, Finland. 
 
Overall C, Lopéz-Otín C. Strategies for MMP inhibition in cancer: innovations for the 
post-trial era. Nat Rev Cancer 2, 657-672, 2002. 
 
Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1, 571–
573, 1889. 
 
Park HI, Ni J, Gerkema FE, Liu D, Belozerov VE, Sang QX. Identification and 
characterization of human endometase (Matrix metalloproteinase-26) from 
endometrial tumor. J Biol Chem 275, 20540-20544, 2000. 
 
Parks WC, Wilson CL, López-Boado YS. Matrix metalloproteinases as modulators of 
inflammation and innate immunity. Nat Rev Immunol 4, 617-629, 2004. 
 
Parks WC, Sudbeck BD, Doyle GR, Saarialho-Kere UK. Matrix metalloproteinases in 
tissue repair. In: Matrix metalloproteinases. 1st Ed. Academic Press, 1998. San Diego, 
CA, USA. 
 
Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of 
phase I or the termination of phase III trials. Cancer Metastasis Rev 22, 177-203, 
2003. 
 
Pendás AM, Folgueras AR, Llano E, Caterina J, Frerard F, Rodríguez F, Astudillo A, 
Noël A, Birkedal-Hansen H, Lopéz-Otín C. Diet-induced obesity and reduced skin 
cancer susceptibility in matrix metalloproteinase 19-deficient mice. Mol Cell Biol 24, 
5304-5313, 2004. 
 
Pendás AM, Knäuper V, Puente XS, Llano E, Matter MG, Apte S, Murphy G, Lopéz-
Otín C. Identification and characterization of a novel human matrix metalloproteinase 
with unique structural characteristics, chromosomal location, and tissue distribution. J 
Biol Chem 272, 4281-4286, 1997. 
 
Pilka R, Whatling C, Domanski H, Hansson S, Eriksson P, Casslén B. Epithelial 
expression of matrix metalloproteinase-26 is elevated in mid-cycle in the human 
endometrium. Mol Hum Reprod 9, 271-277, 2003. 
 
 64
Pirilä E, Sharabi A, Salo T, Quaranta V, Tu H, Heljasvaara R, Koshikawa N, Sorsa T, 
Maisi P. Matrix metalloproteinases process the laminin-5 γ2-chain and regulate 
epithelial cell migration. Biochem Biophys Res Commun 303, 1012-1017, 2003. 
 
Presland RB, Dale BA. Epithelial structural proteins of the skin and oral cavity: 
function in health and disease. Crit Rev Oral Med 11, 383-408, 2000. 
 
Puente XS, Sanchez LM, Gutierrez-Fernandez A, Velasco G, Lopez-Otin C. A 
genomic view of the complexity of mammalian proteolytic systems. Biochem Soc 
Trans 33, 331-334, 2005. 
 
Radisky DC, Bissell MJ. Cancer. Respect thy neighbor! Science 303, 775-777, 2004. 
 
Rechardt O, Elomaa O, Vaalamo M, Pääkkönen K, Jahkola T, Höök-Nikanne J, 
Hembry RM, Häkkinen L, Kere J, Saarialho-Kere U. Stromelysin-2 is upregulated 
during normal wound repair and is induced by cytokines. J Invest Dermatol 115, 778–
787, 2000. 
 
Rhee JS, Diaz R, Korets L, Hodgson JG, Coussens LM. TIMP-1 alters susceptibility 
to carcinogenesis. Cancer Res 64, 952-961, 2004. 
 
Riddick ACP, Shukla CJ, Pennington CJ, Bass R, Nuttall RK, Hogan A, Sethia KK, 
Ellis V, Collins At, Maitland NJ, Ball YR, Edwards DR. Identification of degradome 
components associated with prostate cancer progression by expression analysis of 
human prostatic tissues. Br J Cancer 92, 2171-2180, 2005. 
 
Rockett JC, Larkin K, Darnton SJ, Morris AG, Matthews HR. Five newly established 
oesophageal carcinoma cell lines: phenotypic and immunological characterization. Br 
J Cancer 75, 258-263, 1997. 
 
Rosai J. Gastrointestinal tract. In: Rosai and Ackerman’s Surgical Pathology. Mosby, 
New York, USA, 2004, pp. 615-628. 
 
Ross LJ, Romrell MH. The intergumentary system. In: Histology, a text and atlas. 
Williams & Wilkins, Baltimore, USA, 1989, pp.347-356. 
 
Rudolph-Owen LA, Chan R, Muller WJ, Matrisian LM. The matrix metalloproteinase 
matrilysin influences early-stage mammary tumorigenesis. Cancer Res 58, 5500-
5506, 1998. 
 
Saarialho-Kere U, Kerkelä E, Jahkola T, Keski-Oja J, Lohi J. Epilysin (MMP-28) is 
associated with cell proliferation during epithelial repair. J Invest Dermatol 119, 14–
21, 2002. 
 
Sadowski T, Dietrich S, Koschinsky F, Ludwig A, Proksch E, Titz B, Sedlacek R. 
Matrix metalloproteinase 19 processes the laminin 5 gamma 2 chain and induces 
epithelial cell migration. Cell Mol Life Sci 62, 870-880, 2005. 
 
 65
Saeki H, Tanaka S, Sugimachi K, Kimura Y, Miyazaki M, Ohga T, Sugimachi K. 
Interrelation between expression of matrix metalloproteinase 7 and beta-catenin in 
esophageal cancer. Dig Dis Sci 47, 2738-2742, 2002. 
 
Samantaray S, Sharma R, Chattopadhyaya TK, Gupta SD, Ralhan R. Increased 
expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. J Cancer 
Res Clin Oncol 130, 37-44, 2004. 
 
Schwartz RA. Keratoacanthoma: a clinico-pathologic enigma. Dermatol Surg 30, 
326-333, 2004. 
 
Seidensticker MJ, Behrens J. Biochemical interactions in the wnt pathway. Biochim 
Biophys Acta 1495, 168-182, 2000. 
 
Shimada Y, Imamura M, Wagata T, Yamaguchi N, Tobe T. Characterization of 21 
newly established esophageal cancer cell lines. Cancer 69, 277-284, 1992. 
 
Sternlich MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu 
Rev Cell Biol 17, 463-516, 2001. 
 
Sternlicht MD, Lochter A, Sympson CJ, Huey B, Rougier J-P, Gray JW, Pinkel D, 
Missell MJ, Werb Z. The stromal proteinase MMP3/stromelysin-1 promotes 
mammary carcinogenesis. Cell 87, 137-146, 1999. 
 
Stickens D, Behonick DJ, Ortega N, Heyer B, Hartenstein B, Yu Y, Fosang AJ, 
Schorpp-Kistner M, Angel P, Werb Z. Altered endochondral bone development in 
matrix metalloproteinase 13-deficient mice. Development 131, 5883-5895, 2004. 
 
Sudbeck BD, Baumann P, Ryan GJ, Breitkopf K, Nischt R, Krieg T and Mauch C. 
Selective loss of PMA-stimulated expression of matrix metalloproteinase 1 in HaCaT 
keratinocytes is correlated with the inability to induce mitogen-activated protein 
family kinases. Biochem J 339, 167-175, 1999. 
 
Suzuki AS, Tadano Y, Yamamoto T, Abe S-I, Tajima T. Expression of a novel matrix 
metalloproteinase gene during cynops early embryogenesis. Biochem Biophys Res 
Commun 288, 380-384, 2001.  
 
Tanioka Y, Yoshida T, Yagawa T, Saiki Y, Takeo S, Harada T, Okazawa T, Yanai H, 
Okita K. Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated 
with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer 89, 2116-
2121, 2003. 
 
Timpl R. Macromolecular organization of basement membranes. Curr Opin Cell Biol 
8, 618-624, 1996. 
 
Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC. 
Association of transforming growth factor-beta 1 with prostate cancer: An 
immunohistochemical study. Hum Pathol 24, 4–9, 1993. 
 
 66
Tsukifuji R, Tagawa K, Hatamochi A, Shinkai H. Expression of matrix 
metalloproteinase-1 -2, and -3 in squamous cell carcinoma and actinic keratosis. Br J 
Cancer 80, 1087-1091, 1999. 
 
Tunuguntla R, Ripley D, Sang QX, Chegini N. Expression of matrix 
metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in 
benign endometrium and endometrial cancer. Gynecol Oncol 89, 453-459, 2003. 
 
Uchi H, Terao H, Koga T, Furue M. Cytokines and chemokines in the epidermis. J 
Derm Sci 24, S29-S38, 2000. 
 
Uría JA, Lopéz-Otín C. Matrilysin-2, a new matrix metalloproteinase expressed in 
human tumors and showing the minimal domain organization required for secretion, 
latency, and activity. Cancer Res 60, 4745-4751, 2000. 
 
Vaalamo M, Weckroth M, Puolakkainen P, Saarinen P, Kere J, Lauharanta J, 
Saarialho-Kere U. Patterns of matrix metalloproteinase and TIMP-1 expression in 
chronic and normally healing human cutaneous wounds. Br J Dermatol 135, 52–59, 
1996. 
 
Velasco G, Pendás AM, Fueyo A, Knäuper V, Murphy G, Lopez-Otin C. Cloning and 
characterization of human MMP-23, a new matrix metalloproteinase predominantly 
expressed in reproductive tissues and lacking conserved domains in other family 
members. J Biol Chem 274, 4570-4576, 1999. 
 
Vihinen P, Ala-aho R, Kähäri VM. Matrix metalloproteinases as therapeutic targets in 
cancer. Curr Cancer Drug Targets 5, 203-220, 2005. 
  
Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal 
physiology. Genes Dev 14, 2123-2133, 2000. 
 
Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, 
Senior RM, Werb Z. MMP-9/gelatinase B is a key regulator of growth plate 
angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93, 411-422, 1998. 
 
Wang Z, Jutterman R, Soloway PD. TIMP-2 is required for efficient activation of 
proMMP-2 in vivo. J Biol Chem 275, 26411-26415, 2000. 
 
Weedon D. Malignant tumors. In: Skin pathology. Churchill & Livingstone, London, 
UK, 2002, pp. 765–776. 
 
Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. 
Physiol Rev, 83, 835-870, 2003. 
 
Wilson CL, Ouellette AJ, Satchell DP, Ayabe T, Lopez-Boado YS, Stratman JL, 
Hultgren SJ, Matrisian LM, Parks WC. Regulation of intestinal alpha-defensin 
activation by the metalloproteinase matrilysin in innate host defense. Science 286, 
113-117, 1999. 
 
 67
 68
Wilson CL, Heppner KJ, Labosky PA, Hogan BL, Matrisian LM. Intestinal 
tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc 
Natl Acad Sci USA 94, 1402-1407, 1997. 
 
Witty JP, Lempka T, Coffey RJ, Matrisian LM. Decreased tumor formation in 7,12-
dimethylbenzanthrazene-treated stromelysin-1 transgenic mice is associated with 
alterations in mammary epithelial cell apoptosis. Cancer Res 55, 1401-1406, 1995. 
 
Wyke JA. Overview – burgeoning promise in metastasis research. Eur J Cancer 36, 
1589-1594, 2000. 
 
Yamamoto H, Itoh F, Iku S, Hosokawa M, Imai K. Expression of the gamma(2) chain 
of laminin-5 at the invasive front is associated with recurrence and poor prognosis in 
human esophageal squamous cell carcinoma. Clin Cancer Res 7, 896-900, 2001. 
 
Yamashita K, Tanaka Y, Mimori K, Inoue H, Mori M. Differential expression of 
MMP and uPA systems and prognostic relevance of their expression in esophageal 
squamous cell carcinoma. Int J Cancer 110, 201-207. 2004. 
 
Yamazaki M, Akahane T, Buck T, Yoshiji H, Gomez DE, Schoeffner DJ, Okajima E, 
Harris SR, Bunce OR, Thorgeirsson SS, Thorgeirsson UP. Long-term exposure to 
elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of 
mammary carcinomas in transgenic mice. Carcinogenesis 25, 1735-1746, 2004. 
 
Yang M, Murray M, Kurkinen M. A novel matrix metalloproteinase gene (XMMP) 
encoding vitronectin-like motifs is transiently expressed in Xenopus laevis early 
embryo development. J Biol Chem 272, 13527-13533, 1997. 
 
Yurchenko PD, Amenta PS, Patton BL. Basement membrane assembly, stability and 
activities observed through a developmental lens. Matrix Biol 22, 521-538, 2004. 
 
Zhang J, Cao YJ, Zhao YG, Sang QX, Duan EK. Expression of matrix 
metalloproteinase-26 and tissue inhibitor of metalloproteinase-4 in human normal 
cytotrophoblast cells and a choriocarcinoma cell line, JEG-3. Mol Hum Reprod 8, 
659-666, 2002. 
 
Zhao YG, Xiao AZ, Park HI, Newcomer RG, Yan M, Man YG, Heffelfinger SC, 
Sang QX. Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its 
inhibition by tissue inhibitors of metalloproteinases-2 and -4: A putative role in the 
initiation of breast cancer invasion. Cancer Res 64, 590–598, 2004. 
 
 
 
 
 
